1
|
Cione E, Mahjoubin-Tehran M, Bacchetti T, Banach M, Ferretti G, Sahebkar A. Profiling of differentially expressed MicroRNAs in familial hypercholesterolemia via direct hybridization. Noncoding RNA Res 2024; 9:796-810. [PMID: 38590435 PMCID: PMC10999490 DOI: 10.1016/j.ncrna.2024.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 02/24/2024] [Accepted: 02/25/2024] [Indexed: 04/10/2024] Open
Abstract
Background Individuals with homozygous familial hypercholesterolemia (HoFH) have a severe clinical problem in their first decade of life, which is not usually present in heterozygous FH (HeFH) individuals. For this latter group of patients, FH diagnosis is mostly severely delayed with a significant increase in the risk of angina, myocardial infarction, peripheral artery disease, stroke, and cardiovascular and all-cause mortality. Methods This study used various bioinformatics tools to analyze microarray data and identify critical miRNAs and their target genes associated with FH and its severity. Differentially expressed serum miRNAs from direct hybridization microarray data in three groups of subjects: healthy, HeFH, and HoFH. The differential expressed miRNAs were determined according to a log of fold-change (LFC) <-0.5 or >0.5 and of p < 0.05. Then, we assessed their target genes in silico. Gene ontology (GO) enrichment was applied by Cytoscape. The protein-protein interaction and co-expression network were analyzed by the STRING and GeneMANIA plugins of Cytoscape, respectively. Results We identified increased expression of circulating hsa-miR-604, hsa-miR-652-5p, and hsa-miR-4451 as well as reduced expression of hsa-miR-3140-3p, hsa-miR-550a-5p, and hsa-miR-363-3p in both group of FH vs. healthy subjects. Higher levels of hsa-miR-1183, hsa-miR-1185-1-3p, hsa-miR-122-5p, hsa-miR-19a-3p, hsa-miR-345-3p, and hsa-miR-34c-5p were detected in HeFH in respect to HoFH when compared to healthy subjects. Most upregulated miRNAs mainly affected gene related to cardiac myofibrillogenesis, cholesterol synthesis, RNA editing for apolipoprotein B, and associated with LDL-cholesterol levels. In contrast, down-regulated miRNAs mainly affected gene related to plasma biomarker for coronary artery disease, lipids metabolism, cell adhesion and migration, genetic predictors of type 2 diabetes and cholesterol metabolism. The essential genes were primarily enriched in GO regarding biological regulation, intracellular nucleic acid binding, and the KEGG pathway of TGF-β signaling. Conclusions The case-control nature of this study precluded the possibility of assessing the predictive role of the identified differentially expressed miRNAs for cardiovascular events. Therefore, the signature of miRNAs reflecting the pathogenesis of both HeFH and HoFH.
Collapse
Affiliation(s)
- Erika Cione
- Department of Pharmacy, Health, and Nutritional Sciences. Via Savinio, University of Calabria 87036 Rende (CS) Italy
| | - Maryam Mahjoubin-Tehran
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Maciej Banach
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL) Lodz, Poland
- Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland
- Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe St, Carnegie 591, Baltimore, MD 21287, USA
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
- Center of Obesity, Marche Polytechnic University, 60131 Ancona, Italy
| | - Amirhossein Sahebkar
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
2
|
Bacchetti T, Morresi C, Ferretti G, Larsson A, Åkerfeldt T, Svensson M. Effects of Seven Weeks of Combined Physical Training on High-Density Lipoprotein Functionality in Overweight/Obese Subjects. Metabolites 2023; 13:1068. [PMID: 37887393 PMCID: PMC10609075 DOI: 10.3390/metabo13101068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2023] [Revised: 09/28/2023] [Accepted: 10/06/2023] [Indexed: 10/28/2023] Open
Abstract
Our study aimed to investigate the effects of exercise on HDL composition and functional properties in overweight/obese subjects. Eighteen overweight/obese subjects (nine F and nine M, BMI = 30.3 ± 3 kg/m2) attended supervised training for 7 weeks. The protocol included combined resistance and conditioning training four to five times each week. The activity of the antioxidant enzyme paraoxonase-1 (PON1) associated with HDL was evaluated in all subjects before and after the training intervention. Moreover, myeloperoxidase (MPO) levels and oxidative stress markers (ox-LDLs and total antioxidant capacity) were studied in the serums of the subjects. At the end of the intervention, the activity of PON1 was increased (p < 0.0001), and MPO levels and the MPO/PON1 ratio were decreased (p < 0.0001). In addition, a significant improvement in muscle strength and maximal oxygen uptake (VO2max) (p < 0.0001) and a significant reduction in total and visceral adipose tissue mass (p < 0.001) and waist circumference (p < 0.008), without any significant decrease in body weight, were observed. A significant correlation was established between serum MPO/PON ratios, HDL redox activity and ox-LDLs. In conclusion, our results demonstrate that exercise training, without modifications of dietary habits, improved HDL functionality in overweight/obese adults, without any significant reduction in BMI or modifications of glucose and lipid biochemical parameters.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy;
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy;
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy;
- Center for Health Promotion, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Anders Larsson
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden; (A.L.); (T.Å.)
| | - Torbjörn Åkerfeldt
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden; (A.L.); (T.Å.)
| | - Michael Svensson
- Section of Sports Medicine, Department of Community Medicine and Rehabilitation, Umeå University, 90 187 Umeå, Sweden;
- Umeå School of Sport Sciences, Umeå University, 90 187 Umeå, Sweden
| |
Collapse
|
3
|
Morresi C, Luccarini A, Marcheggiani F, Ferretti G, Damiani E, Bacchetti T. Modulation of paraoxonase-2 in human dermal fibroblasts by UVA-induced oxidative stress: A new potential marker of skin photodamage. Chem Biol Interact 2023; 384:110702. [PMID: 37717644 DOI: 10.1016/j.cbi.2023.110702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 09/05/2023] [Accepted: 09/08/2023] [Indexed: 09/19/2023]
Abstract
Paraoxonase-2 (PON2) is an intracellular protein, that exerts a protective role against cell oxidative stress and apoptosis. Genetic and environmental factors (i.e. dietary factors, cigarette smoke, drugs) are able to modulate cellular PON2 levels. The effect of ultraviolet A radiation (UVA), the oxidizing component of sunlight, on PON2 in human dermal fibroblasts (HuDe) has not been previously explored. Excessive UVA radiation is known to cause direct and indirect skin damage by influencing intracellular signalling pathways through oxidative stress mediated by reactive oxygen species (ROS) that modulate the expression of downstream genes involved in different processes, e.g. skin photoaging and cancer. The aim of this study was, therefore, to investigate the modulation of PON2 in terms of protein expression and enzyme activity in HuDe exposed to UVA (270 kJ/m2). Our results show that PON2 is up-regulated immediately after UVA exposure and that its levels and activity decrease in the post-exposure phase, in a time-dependent manner (2-24 h). The trend in PON2 levels mirror the time-course study of UVA-induced ROS. To confirm this, experiments were also performed in the presence of a SPF30 sunscreen used as shielding agent to revert modulation of PON2 at 0 and 2 h post-UVA exposure where other markers of photo-oxidative stress were also examined (NF-KB, γH2AX, advanced glycation end products). Overall, our results show that the upregulation of PON2 might be related to the increase in intracellular ROS and may play an important role in mitigation of UVA-mediated damage and in the prevention of the consequences of UV exposure, thus representing a new marker of early-response to UVA-induced damage in skin fibroblasts.
Collapse
Affiliation(s)
- Camilla Morresi
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, Ancona 60131, Italy
| | - Alessia Luccarini
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, Ancona 60131, Italy
| | - Fabio Marcheggiani
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, Ancona 60131, Italy
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology, Marche Polytechnic University, Via Brecce Bianche, Ancona 60131, Italy
| | - Elisabetta Damiani
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, Ancona 60131, Italy.
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, Ancona 60131, Italy.
| |
Collapse
|
4
|
Bellachioma L, Morresi C, Albacete A, Martínez-Melgarejo PA, Ferretti G, Giorgini G, Galeazzi R, Damiani E, Bacchetti T. Insights on the Hypoglycemic Potential of Crocus sativus Tepal Polyphenols: An In Vitro and In Silico Study. Int J Mol Sci 2023; 24:ijms24119213. [PMID: 37298165 DOI: 10.3390/ijms24119213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/19/2023] [Accepted: 05/23/2023] [Indexed: 06/12/2023] Open
Abstract
Post-prandial hyperglycemia typical of diabetes mellitus could be alleviated using plant-derived compounds such as polyphenols, which could influence the activities of enzymes involved in carbohydrate digestion and of intestinal glucose transporters. Here, we report on the potential anti-hyperglycemic effect of Crocus sativus tepals compared to stigmas, within the framework of valorizing these by-products of the saffron industry, since the anti-diabetic properties of saffron are well-known, but not those of its tepals. In vitro assays showed that tepal extracts (TE) had a greater inhibitory action than stigma extracts (SE) on α-amylase activity (IC50: TE = 0.60 ± 0.09 mg/mL; SE = 1.10 ± 0.08 mg/mL; acarbose = 0.051 ± 0.07) and on glucose absorption in Caco-2 differentiated cells (TE = 1.20 ± 0.02 mg/mL; SE = 2.30 ± 0.02 mg/mL; phlorizin = 0.23 ± 0.01). Virtual screening performed with principal compounds from stigma and tepals of C. sativus and human pancreatic α-amylase, glucose transporter 2 (GLUT2) and sodium glucose co-transporter-1 (SGLT1) were validated via molecular docking, e.g., for human pancreatic α-amylase, epicatechin 3-o-gallate and catechin-3-o-gallate were the best scored ligands from tepals (-9.5 kcal/mol and -9.4 kcal/mol, respectively), while sesamin and episesamin were the best scored ones from stigmas (-10.1 kcal/mol). Overall, the results point to the potential of C. sativus tepal extracts in the prevention/management of diabetes, likely due to the rich pool of phytocompounds characterized using high-resolution mass spectrometry, some of which are capable of binding and interacting with proteins involved in starch digestion and intestinal glucose transport.
Collapse
Affiliation(s)
- Luisa Bellachioma
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Alfonso Albacete
- Centro de Edafología y Biología Aplicada del Segura, Agencia Estatal Consejo Superior de Investigaciones Científicas (CEBAS-CSIC), Department of Plant Nutrition, Campus Universitario de Espinardo, E-30100 Murcia, Spain
| | - Purificación A Martínez-Melgarejo
- Centro de Edafología y Biología Aplicada del Segura, Agencia Estatal Consejo Superior de Investigaciones Científicas (CEBAS-CSIC), Department of Plant Nutrition, Campus Universitario de Espinardo, E-30100 Murcia, Spain
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Giorgia Giorgini
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Roberta Galeazzi
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Elisabetta Damiani
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Marche Polytechnic University, Via Brecce Bianche, 60131 Ancona, Italy
| |
Collapse
|
5
|
De Simoni E, Rizzetto G, Molinelli E, Lucarini G, Mattioli-Belmonte M, Capodaglio I, Ferretti G, Bacchetti T, Offidani A, Simonetti O. Metabolic Comorbidities in Pediatric Atopic Dermatitis: A Narrative Review. Life (Basel) 2022; 13:life13010002. [PMID: 36675951 PMCID: PMC9866487 DOI: 10.3390/life13010002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Revised: 12/12/2022] [Accepted: 12/14/2022] [Indexed: 12/24/2022]
Abstract
Atopic dermatitis (AD) is an itchy dermatitis with multifactorial aetiology, chronic-recurrent course, and typical distribution of lesions according to the age, affecting the 10-20% of pediatric population. Patients with AD, including children, suffer from many metabolic comorbidities, including metabolic syndrome, being overweight, obesity, dyslipidaemia, and arterial hypertension, all of which had a prevalence that was demonstrated to be higher than in healthy patients. The association between AD and metabolic comorbidities is multifactorial and involves the deregulation of immune system. In fact, hypertrophic adipose tissue produces soluble adipokines involved in inflammation and immunity, which stimulate the production of pro-inflammatory cytokines, responsible for a chronic low-grade inflammatory state and a higher predisposition to hypersensitivity reactions. Especially in pediatric population with AD, these metabolic disorders are usually underestimated and are associated with long term sequelae and an increased risk of a cardiovascular event, which may also occur later in adult age. Therefore, metabolic comorbidities should be carefully evaluated and early treated in children with AD, to minimize the long-term risk of cardiovascular events.
Collapse
Affiliation(s)
- Edoardo De Simoni
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy
| | - Giulio Rizzetto
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy
| | - Elisa Molinelli
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy
| | - Guendalina Lucarini
- Department of Clinical and Molecular Sciences-Histology, Polytechnic University of Marche, 60020 Ancona, Italy
- Correspondence: ; Tel.: +39-0712206075
| | - Monica Mattioli-Belmonte
- Department of Clinical and Molecular Sciences-Histology, Polytechnic University of Marche, 60020 Ancona, Italy
| | - Irene Capodaglio
- Hospital Cardiology and UTIC, Ospedali Riuniti di Ancona, 60126 Ancona, Italy
| | - Gianna Ferretti
- Research Center of Health Education and Health Promotion, Department of Clinical Experimental Science and Odontostomatology-Biochemistry, 60126 Ancona, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences-Biochemistry, Polytechnic University of Marche, 60126 Ancona, Italy
| | - Annamaria Offidani
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy
| | - Oriana Simonetti
- Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy
| |
Collapse
|
6
|
Bacchetti T, Campagna R, Sartini D, Cecati M, Morresi C, Bellachioma L, Martinelli E, Rocchetti G, Lucini L, Ferretti G, Emanuelli M. C. spinosa L. subsp. rupestris Phytochemical Profile and Effect on Oxidative Stress in Normal and Cancer Cells. Molecules 2022; 27:molecules27196488. [PMID: 36235028 PMCID: PMC9573631 DOI: 10.3390/molecules27196488] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 09/27/2022] [Accepted: 09/28/2022] [Indexed: 11/07/2022]
Abstract
Spices, widely used to improve the sensory characteristics of food, contain several bioactive compounds as well, including polyphenols, carotenoids, and glucosynolates. Acting through multiple pathways, these bioactive molecules affect a wide variety of cellular processes involved in molecular mechanisms important in the onset and progress of human diseases. Capparis spinosa L. is an aromatic plant characteristic of the Mediterranean diet. Previous studies have reported that different parts (aerial parts, roots, and seeds) of C. spinosa exert various pharmacological activities. Flower buds of C. spinosa contain several bioactive compounds, including polyphenols and glucosinolates. Two different subspecies of C. spinosa L., namely, C. spinosa L. subsp. spinosa, and C. spinosa L. subsp. rupestris, have been reported. Few studies have been carried out in C. spinosa L. subsp. rupestris. The aim of our study was to investigate the phytochemical profile of floral buds of the less investigated species C. spinosa subsp. rupestris. Moreover, we investigated the effect of the extract from buds of C. spinosa subsp. rupestris (CSE) on cell proliferation, intracellular ROS levels, and expression of the antioxidant and anti-apoptotic enzyme paraoxonase-2 (PON2) in normal and cancer cells. T24 cells and Caco-2 cells were selected as models of advanced-stage human bladder cancer and human colorectal adenocarcinoma, respectively. The immortalized human urothelial cell line (UROtsa) and human dermal fibroblast (HuDe) were chosen as normal cell models. Through an untargeted metabolomic approach based on ultra-high-performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UHPLC-QTOF-MS), our results demonstrate that C. spinosa subsp. rupestris flower buds contain polyphenols and glucosinolates able to exert a higher cytotoxic effect and higher intracellular reactive oxygen species (ROS) production in cancer cells compared to normal cells. Moreover, upregulation of the expression of the enzyme PON2 was observed in cancer cells. In conclusion, our data demonstrate that normal and cancer cells are differentially sensitive to CSE, which has different effects on PON2 gene expression as well. The overexpression of PON2 in T24 cells treated with CSE could represent a mechanism by which tumor cells protect themselves from the apoptotic process induced by glucosinolates and polyphenols.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
- Correspondence: (T.B.); (G.F.)
| | - Roberto Campagna
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
| | - Davide Sartini
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
| | - Monia Cecati
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
| | - Camilla Morresi
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
| | - Luisa Bellachioma
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
| | - Erika Martinelli
- Department for Sustainable Food Process, Università Cattolica del Sacro Cuore, 29122 Piacenza, Italy
| | - Gabriele Rocchetti
- Department for Sustainable Food Process, Università Cattolica del Sacro Cuore, 29122 Piacenza, Italy
| | - Luigi Lucini
- Department for Sustainable Food Process, Università Cattolica del Sacro Cuore, 29122 Piacenza, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
- Correspondence: (T.B.); (G.F.)
| | - Monica Emanuelli
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
- New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, 60131 Ancona, Italy
| |
Collapse
|
7
|
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]. Rev Mal Respir 2022; 39:e35-e106. [PMID: 35752506 DOI: 10.1016/j.rmr.2022.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. METHODS Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. RESULTS After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. CONCLUSION These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis.
Collapse
Affiliation(s)
- V Cottin
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France; UMR 754, IVPC, INRAE, Université de Lyon, Université Claude-Bernard Lyon 1, Lyon, France; Membre d'OrphaLung, RespiFil, Radico-ILD2, et ERN-LUNG, Lyon, France.
| | - P Bonniaud
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et soins intensifs respiratoires, centre hospitalo-universitaire de Bourgogne et faculté de médecine et pharmacie, université de Bourgogne-Franche Comté, Dijon ; Inserm U123-1, Dijon, France
| | - J Cadranel
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et oncologie thoracique, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Tenon, Paris ; Sorbonne université GRC 04 Theranoscan, Paris, France
| | - B Crestani
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - S Jouneau
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Pontchaillou, Rennes ; IRSET UMR1085, université de Rennes 1, Rennes, France
| | - S Marchand-Adam
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, hôpital Bretonneau, service de pneumologie, CHRU, Tours, France
| | - H Nunes
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie, AP-HP, hôpital Avicenne, Bobigny ; université Sorbonne Paris Nord, Bobigny, France
| | - L Wémeau-Stervinou
- Centre de référence constitutif des maladies pulmonaires rares, Institut Cœur-Poumon, service de pneumologie et immuno-allergologie, CHRU de Lille, Lille, France
| | - E Bergot
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie et oncologie thoracique, hôpital Côte de Nacre, CHU de Caen, Caen, France
| | - E Blanchard
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Haut Levêque, CHU de Bordeaux, Pessac, France
| | - R Borie
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - A Bourdin
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, Montpellier ; Inserm U1046, CNRS UMR 921, Montpellier, France
| | - C Chenivesse
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et d'immuno-allergologie, hôpital Albert Calmette ; CHRU de Lille, Lille ; centre d'infection et d'immunité de Lille U1019 - UMR 9017, Université de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, Lille, France
| | - A Clément
- Centre de ressources et de compétence de la mucoviscidose pédiatrique, centre de référence des maladies respiratoires rares (RespiRare), service de pneumologie pédiatrique, hôpital d'enfants Armand-Trousseau, CHU Paris Est, Paris ; Sorbonne université, Paris, France
| | - E Gomez
- Centre de compétence pour les maladies pulmonaires rares, département de pneumologie, hôpitaux de Brabois, CHRU de Nancy, Vandoeuvre-les Nancy, France
| | - A Gondouin
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Jean-Minjoz, Besançon, France
| | - S Hirschi
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, Nouvel Hôpital civil, Strasbourg, France
| | - F Lebargy
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Maison Blanche, Reims, France
| | - C-H Marquette
- Centre de compétence pour les maladies pulmonaires rares, FHU OncoAge, département de pneumologie et oncologie thoracique, hôpital Pasteur, CHU de Nice, Nice cedex 1 ; Université Côte d'Azur, CNRS, Inserm, Institute of Research on Cancer and Aging (IRCAN), Nice, France
| | - D Montani
- Centre de compétence pour les maladies pulmonaires rares, centre national coordonnateur de référence de l'hypertension pulmonaire, service de pneumologie et soins intensifs pneumologiques, AP-HP, DMU 5 Thorinno, Inserm UMR S999, CHU Paris-Sud, hôpital de Bicêtre, Le Kremlin-Bicêtre ; Université Paris-Saclay, Faculté de médecine, Le Kremlin-Bicêtre, France
| | - G Prévot
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Larrey, Toulouse, France
| | - S Quetant
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et physiologie, CHU Grenoble Alpes, Grenoble, France
| | - M Reynaud-Gaubert
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, AP-HM, CHU Nord, Marseille ; Aix Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| | - M Salaun
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, oncologie thoracique et soins intensifs respiratoires & CIC 1404, hôpital Charles Nicole, CHU de Rouen, Rouen ; IRIB, laboratoire QuantiIF-LITIS, EA 4108, université de Rouen, Rouen, France
| | - O Sanchez
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et soins intensifs, hôpital européen Georges-Pompidou, AP-HP, Paris, France
| | | | - K Berkani
- Clinique Pierre de Soleil, Vetraz Monthoux, France
| | - P-Y Brillet
- Université Paris 13, UPRES EA 2363, Bobigny ; service de radiologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - M Campana
- Service de pneumologie et oncologie thoracique, CHR Orléans, Orléans, France
| | - L Chalabreysse
- Service d'anatomie-pathologique, groupement hospitalier est, HCL, Bron, France
| | - G Chatté
- Cabinet de pneumologie et infirmerie protestante, Caluire, France
| | - D Debieuvre
- Service de pneumologie, GHRMSA, hôpital Emile-Muller, Mulhouse, France
| | - G Ferretti
- Université Grenoble Alpes, Grenoble ; service de radiologie diagnostique et interventionnelle, CHU Grenoble Alpes, Grenoble, France
| | - J-M Fourrier
- Association Pierre-Enjalran Fibrose Pulmonaire Idiopathique (APEFPI), Meyzieu, France
| | - N Just
- Service de pneumologie, CH Victor-Provo, Roubaix, France
| | - M Kambouchner
- Service de pathologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - B Legrand
- Cabinet médical de la Bourgogne, Tourcoing ; Université de Lille, CHU Lille, ULR 2694 METRICS, CERIM, Lille, France
| | - F Le Guillou
- Cabinet de pneumologie, pôle santé de l'Esquirol, Le Pradet, France
| | - J-P Lhuillier
- Cabinet de pneumologie, La Varenne Saint-Hilaire, France
| | - A Mehdaoui
- Service de pneumologie et oncologie thoracique, CH Eure-Seine, Évreux, France
| | - J-M Naccache
- Service de pneumologie, allergologie et oncologie thoracique, GH Paris Saint-Joseph, Paris, France
| | - C Paganon
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France
| | - M Rémy-Jardin
- Institut Cœur-Poumon, service de radiologie et d'imagerie thoracique, CHRU de Lille, Lille, France
| | - S Si-Mohamed
- Département d'imagerie cardiovasculaire et thoracique, hôpital Louis-Pradel, HCL, Bron ; Université de Lyon, INSA-Lyon, Université Claude-Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Villeurbanne, France
| | | |
Collapse
|
8
|
Morresi C, Vasarri M, Bellachioma L, Ferretti G, Degl′Innocenti D, Bacchetti T. Glucose Uptake and Oxidative Stress in Caco-2 Cells: Health Benefits from Posidonia oceanica (L.) Delile. Mar Drugs 2022; 20:md20070457. [PMID: 35877750 PMCID: PMC9319946 DOI: 10.3390/md20070457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Revised: 07/12/2022] [Accepted: 07/13/2022] [Indexed: 12/10/2022] Open
Abstract
Posidonia oceanica (L.) Delile is an endemic Mediterranean marine plant of extreme ecological importance. Previous in vitro and in vivo studies have demonstrated the potential antidiabetic properties of P. oceanica leaf extract. Intestinal glucose transporters play a key role in glucose homeostasis and represent novel targets for the management of diabetes. In this study, the ability of a hydroalcoholic P. oceanica leaf extract (POE) to modulate intestinal glucose transporters was investigated using Caco-2 cells as a model of an intestinal barrier. The incubation of cells with POE significantly decreased glucose uptake by decreasing the GLUT2 glucose transporter levels. Moreover, POE had a positive effect on the barrier integrity by increasing the Zonulin-1 levels. A protective effect exerted by POE against oxidative stress induced by chronic exposure to high glucose concentrations or tert-butyl hydroperoxide was also demonstrated. This study highlights for the first time the effect of POE on glucose transport, intestinal barrier integrity, and its protective antioxidant effect in Caco-2 cells. These findings suggest that the P. oceanica phytocomplex may have a positive impact by preventing the intestinal cell dysfunction involved in the development of inflammation-related disease associated with oxidative stress.
Collapse
Affiliation(s)
- Camilla Morresi
- Department of Clinical Experimental Science and Odontostomatology-Biochemistry, Università Politecnica delle Marche, 60100 Ancona, Italy; (C.M.); (G.F.)
| | - Marzia Vasarri
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy;
| | - Luisa Bellachioma
- Department of Life and Environmental Sciences-Biochemistry, Università Politecnica delle Marche, 60100 Ancona, Italy; (L.B.); (T.B.)
| | - Gianna Ferretti
- Department of Clinical Experimental Science and Odontostomatology-Biochemistry, Università Politecnica delle Marche, 60100 Ancona, Italy; (C.M.); (G.F.)
| | - Donatella Degl′Innocenti
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy;
- Interuniversity Center of Marine Biology and Applied Ecology “G. Bacci” (CIBM), Viale N. Sauro 4, 57128 Livorno, Italy
- Correspondence:
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences-Biochemistry, Università Politecnica delle Marche, 60100 Ancona, Italy; (L.B.); (T.B.)
| |
Collapse
|
9
|
Arab ZN, Khayatan D, Razavi SM, Zare K, Kheradkhah E, Momtaz S, Ferretti G, Bacchetti T, Sathyapalan T, Emami SA, Abdolghaffari AH, Sahebkar A. Phytochemicals as Modulators of Paraoxonase-1 in Health and Diseases. Antioxidants (Basel) 2022; 11:antiox11071273. [PMID: 35883764 PMCID: PMC9311866 DOI: 10.3390/antiox11071273] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Revised: 06/22/2022] [Accepted: 06/24/2022] [Indexed: 02/05/2023] Open
Abstract
Chronic diseases such as cardiovascular disease (CVD), atherosclerosis, chronic liver disease, and neurodegenerative diseases are major causes of mortality. These diseases have gained much attention due to their complications, and therefore novel approaches with fewer side effects are an important research topic. Free radicals and oxidative stress are involved in the molecular mechanisms of several diseases. Antioxidants can scavenge free radicals and mitigate their adverse effects. One of the most important antioxidant enzymes are paraoxonases (PONs). These enzymes perform a wide range of physiological activities ranging from drug metabolism to detoxification of neuroleptics. Paraoxonase-1 (PON1) is produced in the liver and then transferred to the bloodstream. It has been demonstrated that PON1 could have beneficial effects in numerous diseases such as atherosclerosis, CVD, diabetes mellitus, and neurodegenerative diseases by modulating relevant signalling pathways involved in inflammation and oxidative stress. These pathways include peroxisome proliferator-activated receptor gamma (PPAR-γ) and protein kinase B/nuclear factor kappa-light-chain-enhancer of activated B cells (AKT/NF-κB)-dependent signalling pathways. Increasing PON1 could potentially have protective effects and reduce the incidence of various diseases by modulating these signalling pathways. Several studies have reported that dietary factors are able to modulate PON1 expression and activity. This review aimed at summarizing the state of the art on the effects of dietary phytochemicals on PON1 enzyme activity and the relevant signalling pathways in different diseases.
Collapse
Affiliation(s)
- Zahra Najafi Arab
- Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; (Z.N.A.); (D.K.); (S.M.R.); (E.K.)
| | - Danial Khayatan
- Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; (Z.N.A.); (D.K.); (S.M.R.); (E.K.)
| | - Seyed Mehrad Razavi
- Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; (Z.N.A.); (D.K.); (S.M.R.); (E.K.)
| | - Kimia Zare
- School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran;
| | - Elnaz Kheradkhah
- Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; (Z.N.A.); (D.K.); (S.M.R.); (E.K.)
| | - Saeideh Momtaz
- Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Tehran, Iran;
- Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), the Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
- GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - Gianna Ferretti
- Department of Clinical Science, Polytechnic University of Marche, Ancona, Italy
- Correspondence: (G.F.); (A.H.A.); (A.S.)
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy;
| | - Thozhukat Sathyapalan
- Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull HU3 2JZ, UK;
| | - Seyed Ahmad Emami
- Department of Traditional Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;
| | - Amir Hossein Abdolghaffari
- Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; (Z.N.A.); (D.K.); (S.M.R.); (E.K.)
- Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Tehran, Iran;
- Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), the Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
- GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
- Correspondence: (G.F.); (A.H.A.); (A.S.)
| | - Amirhossein Sahebkar
- Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
- Correspondence: (G.F.); (A.H.A.); (A.S.)
| |
Collapse
|
10
|
Di Lodovico S, Bacchetti T, D’Ercole S, Covone S, Petrini M, Di Giulio M, Di Fermo P, Diban F, Ferretti G, Cellini L. Complex Chronic Wound Biofilms Are Inhibited in vitro by the Natural Extract of Capparis spinose. Front Microbiol 2022; 13:832919. [PMID: 35479636 PMCID: PMC9035792 DOI: 10.3389/fmicb.2022.832919] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Accepted: 02/24/2022] [Indexed: 12/15/2022] Open
Abstract
Resistant wound microorganisms are becoming an extremely serious challenge in the process of treating infected chronic wounds, leading to impaired healing. Thus, additional approaches should be taken into consideration to improve the healing process. The use of natural extracts can represent a valid alternative to treat/control the microbial infections in wounds. This study investigates the antimicrobial/antivirulence effects of Capparis spinose aqueous extract against the main chronic wound pathogens: Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans. The extract shows phenolic characterization with rutin (1.8 ± 0.14 μg/mg) as the major compound and antibacterial effect against bacteria (S. aureus PECHA 10 MIC 6.25%; P. aeruginosa PECHA 4 MIC 12.50%) without action against C. albicans (MIC and MFC ≥ 50%). Capparis spinose also shows a significant antivirulence effect in terms of antimotility/antibiofilm actions. In particular, the extract acts (i) on P. aeruginosa both increasing its swimming and swarming motility favoring the planktonic phenotype and reducing its adhesive capability, (ii) on S. aureus and P. aeruginosa biofilm formation reducing both the biomass and CFU/ml. Furthermore, the extract significantly displays the reduction of a dual-species S. aureus and P. aeruginosa Lubbock chronic wound biofilm, a complex model that mimics the realistic in vivo microbial spatial distribution in wounds. The results suggest that C. spinose aqueous extract could represent an innovative eco-friendly strategy to prevent/control the wound microbial infection.
Collapse
Affiliation(s)
- Silvia Di Lodovico
- Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Simonetta D’Ercole
- Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Sara Covone
- Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Morena Petrini
- Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Mara Di Giulio
- Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Paola Di Fermo
- Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Firas Diban
- Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
| | - Gianna Ferretti
- Department of Clinical Science, Research Center of Health Education and Health Promotion, Polytechnic University of Marche, Ancona, Italy
| | - Luigina Cellini
- Department of Pharmacy, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
- *Correspondence: Luigina Cellini,
| |
Collapse
|
11
|
Bellachioma L, Rocchetti G, Morresi C, Martinelli E, Lucini L, Ferretti G, Damiani E, Bacchetti T. Valorisation of
Crocus sativus
flower parts for herbal infusions: impact of brewing conditions on phenolic profiling, antioxidant capacity and sensory traits. Int J Food Sci Technol 2022. [DOI: 10.1111/ijfs.15713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Luisa Bellachioma
- Department of Life and Environmental Sciences Marche Polytechnic University Via Brecce Bianche Ancona 60131 Italy
| | - Gabriele Rocchetti
- Department of Animal Science, Food and Nutrition Università Cattolica del Sacro Cuore Via Emilia Parmense 84 Piacenza 29122 Italy
| | - Camilla Morresi
- Department of Life and Environmental Sciences Marche Polytechnic University Via Brecce Bianche Ancona 60131 Italy
| | - Erika Martinelli
- Department for Sustainable Food Process Università Cattolica del Sacro Cuore Via Emilia Parmense 84 Piacenza 29122 Italy
| | - Luigi Lucini
- Department for Sustainable Food Process Università Cattolica del Sacro Cuore Via Emilia Parmense 84 Piacenza 29122 Italy
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology Marche Polytechnic University Via Brecce Bianche Ancona 60131 Italy
| | - Elisabetta Damiani
- Department of Life and Environmental Sciences Marche Polytechnic University Via Brecce Bianche Ancona 60131 Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences Marche Polytechnic University Via Brecce Bianche Ancona 60131 Italy
| |
Collapse
|
12
|
Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]. Rev Mal Respir 2022; 39:275-312. [PMID: 35304014 DOI: 10.1016/j.rmr.2022.01.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. METHODS Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. RESULTS After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. CONCLUSION These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis.
Collapse
Affiliation(s)
- V Cottin
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France; UMR 754, IVPC, INRAE, Université de Lyon, Université Claude-Bernard Lyon 1, Lyon, France; Membre d'OrphaLung, RespiFil, Radico-ILD2, et ERN-LUNG, Lyon, France.
| | - P Bonniaud
- Service de pneumologie et soins intensifs respiratoires, centre de référence constitutif des maladies pulmonaires rares, centre hospitalo-universitaire de Bourgogne et faculté de médecine et pharmacie, université de Bourgogne-Franche Comté, Dijon ; Inserm U123-1, Dijon, France
| | - J Cadranel
- Service de pneumologie et oncologie thoracique, centre de référence constitutif des maladies pulmonaires rares, assistance publique-hôpitaux de Paris (AP-HP), hôpital Tenon, Paris ; Sorbonne université GRC 04 Theranoscan, Paris, France
| | - B Crestani
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - S Jouneau
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Pontchaillou, Rennes ; IRSET UMR1085, université de Rennes 1, Rennes, France
| | - S Marchand-Adam
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, hôpital Bretonneau, service de pneumologie, CHRU, Tours, France
| | - H Nunes
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie, AP-HP, hôpital Avicenne, Bobigny ; université Sorbonne Paris Nord, Bobigny, France
| | - L Wémeau-Stervinou
- Centre de référence constitutif des maladies pulmonaires rares, Institut Cœur-Poumon, service de pneumologie et immuno-allergologie, CHRU de Lille, Lille, France
| | - E Bergot
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie et oncologie thoracique, hôpital Côte de Nacre, CHU de Caen, Caen, France
| | - E Blanchard
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, service de pneumologie, hôpital Haut Levêque, CHU de Bordeaux, Pessac, France
| | - R Borie
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie A, AP-HP, hôpital Bichat, Paris, France
| | - A Bourdin
- Centre de compétence pour les maladies pulmonaires rares de l'adulte, département de pneumologie et addictologie, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, Montpellier ; Inserm U1046, CNRS UMR 921, Montpellier, France
| | - C Chenivesse
- Centre de référence constitutif des maladies pulmonaires rares, service de pneumologie et d'immuno-allergologie, hôpital Albert Calmette ; CHRU de Lille, Lille ; centre d'infection et d'immunité de Lille U1019 - UMR 9017, Université de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, Lille, France
| | - A Clément
- Centre de ressources et de compétences de la mucoviscidose pédiatrique, centre de référence des maladies respiratoires rares (RespiRare), service de pneumologie pédiatrique, hôpital d'enfants Armand-Trousseau, CHU Paris Est, Paris ; Sorbonne université, Paris, France
| | - E Gomez
- Centre de compétence pour les maladies pulmonaires rares, département de pneumologie, hôpitaux de Brabois, CHRU de Nancy, Vandoeuvre-les Nancy, France
| | - A Gondouin
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Jean Minjoz, Besançon, France
| | - S Hirschi
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, Nouvel Hôpital civil, Strasbourg, France
| | - F Lebargy
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Maison Blanche, Reims, France
| | - C-H Marquette
- Centre de compétence pour les maladies pulmonaires rares, FHU OncoAge, département de pneumologie et oncologie thoracique, hôpital Pasteur, CHU de Nice, Nice cedex 1 ; Université Côte d'Azur, CNRS, Inserm, Institute of Research on Cancer and Aging (IRCAN), Nice, France
| | - D Montani
- Centre de compétence pour les maladies pulmonaires rares, centre national coordonnateur de référence de l'hypertension pulmonaire, unité pneumologie et soins intensifs pneumologiques, AP-HP, DMU 5 Thorinno, Inserm UMR S999, CHU Paris-Sud, hôpital de Bicêtre, Le Kremlin-Bicêtre ; Université Paris-Saclay, Faculté de médecine, Le Kremlin-Bicêtre, France
| | - G Prévot
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, CHU Larrey, Toulouse, France
| | - S Quetant
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et physiologie, CHU Grenoble Alpes, Grenoble, France
| | - M Reynaud-Gaubert
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, AP-HM, CHU Nord, Marseille ; Aix Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| | - M Salaun
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie, oncologie thoracique et soins intensifs respiratoires & CIC 1404, hôpital Charles Nicole, CHU de Rouen, Rouen ; IRIB, laboratoire QuantiIF-LITIS, EA 4108, université de Rouen, Rouen, France
| | - O Sanchez
- Centre de compétence pour les maladies pulmonaires rares, service de pneumologie et soins intensifs, hôpital européen Georges Pompidou, AP-HP, Paris, France
| | | | - K Berkani
- Clinique Pierre de Soleil, Vetraz Monthoux, France
| | - P-Y Brillet
- Université Paris 13, UPRES EA 2363, Bobigny ; service de radiologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - M Campana
- Service de pneumologie et oncologie thoracique, CHR Orléans, Orléans, France
| | - L Chalabreysse
- Service d'anatomie-pathologique, groupement hospitalier est, HCL, Bron, France
| | - G Chatté
- Cabinet de pneumologie et infirmerie protestante, Caluire, France
| | - D Debieuvre
- Service de Pneumologie, GHRMSA, hôpital Emile Muller, Mulhouse, France
| | - G Ferretti
- Université Grenoble Alpes, Grenoble ; service de radiologie diagnostique et interventionnelle, CHU Grenoble Alpes, Grenoble, France
| | - J-M Fourrier
- Association Pierre Enjalran Fibrose Pulmonaire Idiopathique (APEFPI), Meyzieu, France
| | - N Just
- Service de pneumologie, CH Victor Provo, Roubaix, France
| | - M Kambouchner
- Service de pathologie, AP-HP, hôpital Avicenne, Bobigny, France
| | - B Legrand
- Cabinet médical de la Bourgogne, Tourcoing ; Université de Lille, CHU Lille, ULR 2694 METRICS, CERIM, Lille, France
| | - F Le Guillou
- Cabinet de pneumologie, pôle santé de l'Esquirol, Le Pradet, France
| | - J-P Lhuillier
- Cabinet de pneumologie, La Varenne Saint-Hilaire, France
| | - A Mehdaoui
- Service de pneumologie et oncologie thoracique, CH Eure-Seine, Évreux, France
| | - J-M Naccache
- Service de pneumologie, allergologie et oncologie thoracique, GH Paris Saint-Joseph, Paris, France
| | - C Paganon
- Centre national coordonnateur de référence des maladies pulmonaires rares, service de pneumologie, hôpital Louis-Pradel, Hospices Civils de Lyon (HCL), Lyon, France
| | - M Rémy-Jardin
- Institut Cœur-Poumon, service de radiologie et d'imagerie thoracique, CHRU de Lille, Lille, France
| | - S Si-Mohamed
- Département d'imagerie cardiovasculaire et thoracique, hôpital Louis Pradel, HCL, Bron ; Université de Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Villeurbanne, France
| | | |
Collapse
|
13
|
Borsato M, Cid Vidal X, Tsai Y, Vázquez Sierra C, Zurita J, Alonso-Álvarez G, Boyarsky A, Brea Rodríguez A, Buarque Franzosi D, Cacciapaglia G, Casais Vidal A, Du M, Elor G, Escudero M, Ferretti G, Flacke T, Foldenauer P, Hajer J, Henry L, Ilten P, Kamenik J, Kishor Jashal B, Knapen S, Kostiuk I, Redi FL, Low M, Liu Z, Oyanguren Campos A, Polycarpo E, Ramos M, Ramos Pernas M, Salvioni E, Rangel MS, Schäfer R, Sestini L, Soreq Y, Tran VQ, Timiryasov I, van Veghel M, Westhoff S, Williams M, Zupan J. Unleashing the full power of LHCb to probe stealth new physics. Rep Prog Phys 2022; 85:024201. [PMID: 34942603 DOI: 10.1088/1361-6633/ac4649] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Accepted: 12/23/2021] [Indexed: 06/14/2023]
Abstract
In this paper, we describe the potential of the LHCb experiment to detect stealth physics. This refers to dynamics beyond the standard model that would elude searches that focus on energetic objects or precision measurements of known processes. Stealth signatures include long-lived particles and light resonances that are produced very rarely or together with overwhelming backgrounds. We will discuss why LHCb is equipped to discover this kind of physics at the Large Hadron Collider and provide examples of well-motivated theoretical models that can be probed with great detail at the experiment.
Collapse
Affiliation(s)
- M Borsato
- Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
| | - X Cid Vidal
- Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Y Tsai
- Maryland Center for Fundamental Physics, Department of Physics, University of Maryland, College Park, MD 20742-4111, United States of America
- Department of Physics, University of Notre Dame, South Bend, IN 46556, United States of America
| | - C Vázquez Sierra
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J Zurita
- Instituto de Física Corpuscular (CSIC-UV), Valencia, Spain
| | - G Alonso-Álvarez
- Department of Physics & McGill Space Institute, McGill University, 3600 Rue University, Montréal, QC, H3A 2T8, Canada
| | - A Boyarsky
- Intituut-Lorentz, Leiden University, 2333 CA Leiden, The Netherlands
| | - A Brea Rodríguez
- Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - D Buarque Franzosi
- Department of Physics, Chalmers University of Technology, Fysikgården, 41296 Göteborg, Sweden
- Physics Department, University of Gothenburg, 41296 Göteborg, Sweden
| | - G Cacciapaglia
- University of Lyon, Université Claude Bernard Lyon 1, F-69001 Lyon, France
- Institut de Physique des 2 Infinis (IP2I) de Lyon, CNRS/UMR5822, F-69622 Villeurbanne, France
| | - A Casais Vidal
- Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - M Du
- Department of Physics, Nanjing University, Nanjing 210093, People's Republic of China
| | - G Elor
- Department of Physics, University of Washington, Seattle, WA 98195, United States of America
| | - M Escudero
- Physik-Department, Technische Universität, München, James-Franck-Straße, 85748 Garching, Germany
| | - G Ferretti
- Department of Physics, Chalmers University of Technology, Fysikgården, 41296 Göteborg, Sweden
| | - T Flacke
- Center for Theoretical Physics of the Universe, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea
| | - P Foldenauer
- Institute for Particle Physics Phenomenology, Durham University, Durham DH1 3LE, United Kingdom
| | - J Hajer
- Centre for Cosmology, Particle Physics and Phenomenology, Université catholique de Louvain, Louvain-la-Neuve B-1348, Belgium
- Department of Physics, Universität Basel, Klingelbergstraße 82, CH-4056 Basel, Switzerland
| | - L Henry
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Instituto de Física Corpuscular (CSIC-UV), Valencia, Spain
- INFN Sezione di Milano, Milano, Italy
| | - P Ilten
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, United States of America
| | - J Kamenik
- Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, Jadranska 19, 1000 Ljubljana, Slovenia
| | | | - S Knapen
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Igor Kostiuk
- Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
| | - F L Redi
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M Low
- Theoretical Physics Department, Fermilab, PO Box 500, Batavia, IL 60510, United States of America
| | - Z Liu
- Department of Physics, Nanjing University, Nanjing 210093, People's Republic of China
- Center for High Energy Physics, Peking University, Beijing 100871, People's Republic of China
- CAS Center for Excellence in Particle Physics, Beijing 100049, People's Republic of China
| | | | - E Polycarpo
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - M Ramos
- CAFPE and Departamento de Física Teórica y del Cosmos, Universidad de Granada, Campus de Fuentenueva, E-18071 Granada, Spain
- Laboratório de Instrumentaçao e Física Experimental de Partículas, Departamento de Física da Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal
| | - M Ramos Pernas
- Department of Physics, University of Warwick, Coventry, United Kingdom
| | - E Salvioni
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M S Rangel
- Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
| | - R Schäfer
- Institute for Theoretical Physics, Heidelberg University, 69120 Heidelberg, Germany
| | - L Sestini
- Istituto Nazionale di Fisica Nucleare (INFN), Padova Division, Padova, Italy
| | - Y Soreq
- Physics Department, Technion-Israel Institute of Technology, Haifa 3200003, Israel
| | - V Q Tran
- Department of Physics, Nanjing University, Nanjing 210093, People's Republic of China
| | - I Timiryasov
- Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - M van Veghel
- Van Swinderen Institute, University of Groningen, Groningen, The Netherlands
| | - S Westhoff
- Institute for Theoretical Physics, Heidelberg University, 69120 Heidelberg, Germany
| | - M Williams
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, MA 02139, United States of America
| | - J Zupan
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, United States of America
| |
Collapse
|
14
|
Pugnaloni S, Alia S, Gabrielli M, Di Paolo A, Turco I, Mazzanti L, Orsini R, Vignini A, Ferretti G. Senatore cappelli ( Triticum turgidum ssp. durum) pasta: a study on the nutritional quality of whole grains and its physical form. Int J Food Sci Nutr 2022; 73:451-459. [PMID: 35016589 DOI: 10.1080/09637486.2021.2025212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Pasta is one of the components of the Mediterranean Diet, despite considerable attention given, its use is still debated. Several studies encouraged the consumption of whole grain because of its many properties and the positive association between refined carbohydrates and insulin resistance, by measuring the Glycaemic Index (GI), an indicator of the physiological effects of a carbohydrate meal. In this study, the GI and polyphenol content of Senatore Cappelli (Triticum turgidum ssp. durum) pasta were evaluated. Using spectrophotometric methods, total polyphenols and flavonoids were found to be 113.5 mg/100 g and 52.96 mg/100 g, respectively. To measure the GI, a standard assay was performed, and values of 47.9 ± 5.2 for long format pasta and 68.5 ± 4.6 for short format pasta were obtained. The present study confirms the presence of polyphenols and flavonoids in pasta Senatore Cappelli. The value of GI is influenced by the pasta shape. These informations could provide valuable data for practitioners preparing personalised diets.
Collapse
Affiliation(s)
- Sofia Pugnaloni
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy
| | - Sonila Alia
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy
| | - Marcello Gabrielli
- Department of Clinical Sciences, School of Specialization in Clinical Nutrition, Università Politecnica delle Marche, Ancona, Italy
| | - Alice Di Paolo
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy
| | - Imma Turco
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy
| | - Laura Mazzanti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy
| | - Roberto Orsini
- Department of Agricultural, Food and Environmental Sciences (D3A), Agronomy and Crop Science Section, Università Politecnica delle Marche, Ancona, Italy
| | - Arianna Vignini
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy.,Research Center of Health Education and Health Promotion, Università Politecnica delle Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Università Politecnica delle Marche, Ancona, Italy.,Research Center of Health Education and Health Promotion, Università Politecnica delle Marche, Ancona, Italy
| |
Collapse
|
15
|
Mazzuferi G, Bacchetti T, Islam MO, Ferretti G. High density lipoproteins and oxidative stress in breast cancer. Lipids Health Dis 2021; 20:143. [PMID: 34696795 PMCID: PMC8543840 DOI: 10.1186/s12944-021-01562-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 09/20/2021] [Indexed: 12/29/2022] Open
Abstract
Breast cancer is one of the main leading causes of women death. In recent years, attention has been focused on the role of lipoproteins, alterations of cholesterol metabolism and oxidative stress in the molecular mechanism of breast cancer. A role for high density lipoproteins (HDL) has been proposed, in fact, in addition to the role of reverse cholesterol transport (RCT), HDL exert antioxidant and anti-inflammatory properties, modulate intracellular cholesterol homeostasis, signal transduction and proliferation. Low levels of HDL-Cholesterol (HDL-C) have been demonstrated in patients affected by breast cancer and it has been suggested that low levels of HDL-C could represent a risk factor of breast cancer. Contrasting results have been observed by other authors. Recent studies have demonstrated alterations of the activity of some enzymes associated to HDL surface such as Paraoxonase (PON1), Lecithin-Cholesterol Acyltransferase (LCAT) and Phospholipase A2 (PLA2). Higher levels of markers of lipid peroxidation in plasma or serum of patients have also been observed and suggest dysfunctional HDL in breast cancer patients. The review summarizes results on levels of markers of oxidative stress of plasma lipids and on alterations of enzymes associated to HDL in patients affected by breast cancer. The effects of normal and dysfunctional HDL on human breast cancer cells and molecular mechanisms potentially involved will be also reviewed.
Collapse
Affiliation(s)
- Gabriele Mazzuferi
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Ancona, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy.
| | - Md Obaidul Islam
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Ancona, Italy
| |
Collapse
|
16
|
Benchagra L, Berrougui H, Islam MO, Ramchoun M, Boulbaroud S, Hajjaji A, Fulop T, Ferretti G, Khalil A. Antioxidant Effect of Moroccan Pomegranate ( Punica granatum L. Sefri Variety) Extracts Rich in Punicalagin against the Oxidative Stress Process. Foods 2021; 10:foods10092219. [PMID: 34574329 PMCID: PMC8469689 DOI: 10.3390/foods10092219] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/11/2021] [Accepted: 09/12/2021] [Indexed: 01/19/2023] Open
Abstract
Natural antioxidants products are widely distributed in food and medicinal plants. These natural antioxidants, especially polyphenols, exhibit a wide range of biological activities including anti-cancer, anti-inflammatory, and anti-atherosclerosis activities. Pomegranate (Punica granatum L.) is a rich source of polyphenolic components. The purpose of this study was to characterize the phenolic composition and flavonoids and anthocyanin content of different parts (peel and aril) of the Sefri variety of pomegranate. Our results showed that Peel extract was richer in these compounds than that of the Arils, especially in Punicalagin (A and B). DPPH free radical scavenging, reducing power (FRAP), β-carotene bleaching, and hydrogen peroxide scavenging assays revealed a greater dose-dependent activity of pomegranate peel phenolic extract (PPPE) compared to pomegranate aril phenolic extract (PAPE). PPPE was also more potent than PAPE concerning its ability to inhibit conjugated diene formation and to reduce α-tocopherol disappearance induced by CuSO4-mediated LDL peroxidation. Interestingly, both extracts (PPPE and PAPE) significantly inhibited lipid peroxidation and the formation of reactive oxygen species (ROS) in stressed J82 human bladder cancer cells. These results reflect the protective effects that this Moroccan variety of pomegranate can provide against the development of metabolic disorder, cancer, atherosclerosis, and cardiovascular disease. Given these properties, further studies should be undertaken to investigate possible applications of Sefri pomegranate extracts in the fields of food preservation and health supplements.
Collapse
Affiliation(s)
- Lamiae Benchagra
- Department of Biology, Polydisciplinary Faculty, University Sultan Moulay Slimane, Beni Mellal 23020, Morocco; (L.B.); (H.B.); (M.R.); (S.B.); (A.H.)
| | - Hicham Berrougui
- Department of Biology, Polydisciplinary Faculty, University Sultan Moulay Slimane, Beni Mellal 23020, Morocco; (L.B.); (H.B.); (M.R.); (S.B.); (A.H.)
- Department of Medicine, Geriatrics Service, Faculty of Medicine and Biological Sciences, University of Sherbrooke, Sherbrooke, QC J1H 4N4, Canada; (M.O.I.); (T.F.)
| | - Mohamed Obaidul Islam
- Department of Medicine, Geriatrics Service, Faculty of Medicine and Biological Sciences, University of Sherbrooke, Sherbrooke, QC J1H 4N4, Canada; (M.O.I.); (T.F.)
- Department of Clinical Science and Odontostomatology (DISCO), Polytechnic University of Marche, I-60126 Ancona, Italy;
| | - Mhamed Ramchoun
- Department of Biology, Polydisciplinary Faculty, University Sultan Moulay Slimane, Beni Mellal 23020, Morocco; (L.B.); (H.B.); (M.R.); (S.B.); (A.H.)
| | - Samira Boulbaroud
- Department of Biology, Polydisciplinary Faculty, University Sultan Moulay Slimane, Beni Mellal 23020, Morocco; (L.B.); (H.B.); (M.R.); (S.B.); (A.H.)
| | - Abdelouahed Hajjaji
- Department of Biology, Polydisciplinary Faculty, University Sultan Moulay Slimane, Beni Mellal 23020, Morocco; (L.B.); (H.B.); (M.R.); (S.B.); (A.H.)
| | - Tamas Fulop
- Department of Medicine, Geriatrics Service, Faculty of Medicine and Biological Sciences, University of Sherbrooke, Sherbrooke, QC J1H 4N4, Canada; (M.O.I.); (T.F.)
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology (DISCO), Polytechnic University of Marche, I-60126 Ancona, Italy;
| | - Abdelouahed Khalil
- Department of Medicine, Geriatrics Service, Faculty of Medicine and Biological Sciences, University of Sherbrooke, Sherbrooke, QC J1H 4N4, Canada; (M.O.I.); (T.F.)
- Correspondence:
| |
Collapse
|
17
|
Sartini D, Campagna R, Lucarini G, Pompei V, Salvolini E, Mattioli-Belmonte M, Molinelli E, Brisigotti V, Campanati A, Bacchetti T, Ferretti G, Offidani A, Emanuelli M. Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. Hum Cell 2021; 34:1929-1931. [PMID: 34302630 DOI: 10.1007/s13577-021-00581-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 07/21/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Davide Sartini
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy
| | - Roberto Campagna
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy
| | - Guendalina Lucarini
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| | - Veronica Pompei
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy
| | - Eleonora Salvolini
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy.
| | | | - Elisa Molinelli
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| | - Valerio Brisigotti
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| | - Anna Campanati
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Marche Polytechnic University, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy
| | - Annamaria Offidani
- Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
| | - Monica Emanuelli
- Department of Clinical Sciences, Marche Polytechnic University, Ancona, Italy.,New York-Marche Structural Biology Center (NY-MaSBiC), Marche Polytechnic University, Ancona, Italy
| |
Collapse
|
18
|
Bacchetti T, Ferretti G, Carbone F, Ministrini S, Montecucco F, Jamialahmadi T, Sahebkar A. Dysfunctional High-density Lipoprotein: The Role of Myeloperoxidase and Paraoxonase-1. Curr Med Chem 2021; 28:2842-2850. [PMID: 32674726 DOI: 10.2174/0929867327999200716112353] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2020] [Revised: 06/20/2020] [Accepted: 06/29/2020] [Indexed: 11/22/2022]
Abstract
Low circulating high-density lipoproteins (HDL) are not only defining criteria for metabolic syndrome, but are more generally associated with atherosclerotic cardiovascular disease (ASCVD) and other chronic diseases. Oxidative stress, a hallmark of cardio-metabolic disease, further influences HDL activity by suppressing their function. Especially the leukocyte- derived enzyme myeloperoxidase (MPO) has recently attracted great interest as it catalyzes the formation of oxidizing reactive species that modify the structure and function of HDL, ultimately increasing cardiovascular risk. Contrariwise, paraoxonase-1 (PON1) is an HDL-associated enzyme that protects HDL from lipid oxidation and then acts as a protective factor against ASCVD. It is noteworthy that recent studies have demonstrated how MPO, PON1 and HDL form a functional complex in which PON1 partially inhibits the MPO activity, while MPO in turn partially inactivates PON1.In line with that, a high MPO/PON1 ratio characterizes patients with ASCVD and metabolic syndrome and has been suggested as a potential marker of dysfunctional HDL as well as a predictor of ASCVD. In this review, we summarize the evidence on the interactions between MPO and PON1 with regard to their structure, function and interaction with HDL activity. We also provide an overview of in vitro and experimental animal models, finally focusing on clinical evidence from a cohort of patients with ASCVD and metabolic syndrome.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences (DiSVA), Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Science and Odontostomatology, Polytechnic University of Marche, Ancona, Italy
| | - Federico Carbone
- First Clinic of Internal Medicine Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy
| | - Stefano Ministrini
- Internal Medicine Department, "Santa Maria della Misericordia" Hospital, University of Perugia, Piazzale Menghini, Sant'Andrea delle Fratte 06132 Perugia, Italy
| | - Fabrizio Montecucco
- IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, 10 Largo Benzi, 16132 Genoa, Italy
| | - Tannaz Jamialahmadi
- Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran
| | | |
Collapse
|
19
|
Bacchetti T, Salvolini E, Pompei V, Campagna R, Molinelli E, Brisigotti V, Togni L, Lucarini G, Sartini D, Campanati A, Mattioli-Belmonte M, Rubini C, Ferretti G, Offidani A, Emanuelli M. Paraoxonase-2: A potential biomarker for skin cancer aggressiveness. Eur J Clin Invest 2021; 51:e13452. [PMID: 33210737 DOI: 10.1111/eci.13452] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 11/04/2020] [Accepted: 11/05/2020] [Indexed: 12/17/2022]
Abstract
BACKGROUND Cutaneous neoplasms include melanoma and non-melanoma skin cancers (NMSCs). Among NMSCs, basal cell carcinoma (BCC) represents the most common lesion. On the contrary, although accounting for less than 5% of all skin cancers, melanoma is responsible for most of cutaneous malignancy-related deaths. Paraoxonase-2 (PON2) is an intracellular enzyme exerting a protective role against production of reactive oxygen species within mitochondrial respiratory chain. Recently, a growing attention has been focused on exploring the role of PON2 in cancer. The aim of this study was to investigate the diagnostic and prognostic role of PON2 in skin neoplasms. MATERIALS AND METHODS 36 cases of BCC, distinguished between nodular and infiltrative lesions, as well as 29 melanoma samples were analysed by immunohistochemistry to evaluate PON2 protein expression. Subsequent statistical analyses were carried out to explore the existence of correlations between intratumour enzyme levels and clinicopathological features. RESULTS Results obtained showed PON2 overexpression in BCCs compared with controls. In particular, distinguishing between less and more aggressive tumour forms, we found no significant differences in enzyme levels between nodular BCCs and controls. Conversely, PON2 expression was significantly higher in infiltrative BCCs compared with controls. Moreover, the enzyme was strongly upregulated in melanoma samples with respect to controls. Interestingly, PON2 levels were positively correlated with Breslow thickness, Clark level, regression, mitoses, lymph node metastases, primary tumour (pT) parameter and pathological stage. CONCLUSIONS Reported findings seem to suggest that PON2 expression levels could be positively related with tumour aggressiveness of both BCC and melanoma.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Eleonora Salvolini
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Veronica Pompei
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Roberto Campagna
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Elisa Molinelli
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Valerio Brisigotti
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Lucrezia Togni
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Guendalina Lucarini
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Davide Sartini
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Anna Campanati
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | | | - Corrado Rubini
- Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Annamaria Offidani
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Monica Emanuelli
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy.,New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, Ancona, Italy
| |
Collapse
|
20
|
Couraud S, Ferretti G, Milleron B, Cortot A, Girard N, Gounant V, Laurent F, Leleu O, Quoix E, Revel MP, Wislez M, Westeel V, Zalcman G, Scherpereel A, Khalil A. [Recommendations of French specialists on screening for lung cancer]. Rev Mal Respir 2021; 38:310-325. [PMID: 33637394 DOI: 10.1016/j.rmr.2021.02.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 01/25/2021] [Indexed: 12/17/2022]
Affiliation(s)
- S Couraud
- Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, hôpital Lyon Sud, Pierre-Bénite, France; Intergroupe francophone de cancérologie thoracique, Paris, France.
| | - G Ferretti
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de radiologie diagnostique et interventionnel, CHU de Grenoble-Alpes, Grenoble, France
| | - B Milleron
- Intergroupe francophone de cancérologie thoracique, Paris, France
| | - A Cortot
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie et oncologie thoracique, CHU de Lille, Lille, France
| | - N Girard
- Intergroupe francophone de cancérologie thoracique, Paris, France; Unité d'oncologie thoracique, institut Curie, Paris, France
| | - V Gounant
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service d'oncologie thoracique, groupe hospitalier Bichat-Claude-Bernard, AP-HP, Paris, France
| | - F Laurent
- Service de radiologie, CHU de Bordeaux, Pessac, France
| | - O Leleu
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie, centre hospitalier Abbeville, Abbeville, France
| | - E Quoix
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie, CHRU Strasbourg, Strasbourg, France
| | - M-P Revel
- Service de radiologie, hôpital Cochin, Paris, France
| | - M Wislez
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service d'oncologie thoracique, hôpital Cochin, Paris, France
| | - V Westeel
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie et cancérologie thoracique, CHU de Besançon, Besançon, France
| | - G Zalcman
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service d'oncologie thoracique, groupe hospitalier Bichat-Claude-Bernard, AP-HP, Paris, France
| | - A Scherpereel
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de pneumologie et oncologie thoracique, CHU de Lille, Lille, France
| | - A Khalil
- Intergroupe francophone de cancérologie thoracique, Paris, France; Service de radiologie, groupe hospitalier Bichat-Claude-Bernard, AP-HP, Paris, France
| |
Collapse
|
21
|
Campagna R, Bacchetti T, Salvolini E, Pozzi V, Molinelli E, Brisigotti V, Sartini D, Campanati A, Ferretti G, Offidani A, Emanuelli M. Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin. Antioxidants (Basel) 2020; 9:antiox9121238. [PMID: 33297311 PMCID: PMC7762224 DOI: 10.3390/antiox9121238] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 12/03/2020] [Accepted: 12/05/2020] [Indexed: 01/10/2023] Open
Abstract
Melanoma represents the most aggressive skin cancer, being responsible for the majority of deaths related with these neoplasms. Despite chemotherapy represents a frontline approach for management of the advanced stages of the disease, it displayed poor response rates and short-term efficacy due to melanoma cell resistance. Therefore, the discovery of molecules that can be used for effective targeted therapy of melanoma is crucial. In this study, we evaluated the impact of paraoxonase-2 (PON2) silencing on proliferation, viability, and resistance to treatment of the A375 melanoma cell line with chemotherapeutic drugs dacarbazine (DTIC) and cisplatin (CDDP). Due to the enzymes ability to counteract oxidative stress, we also evaluated the effect of enzyme knockdown on reactive oxygen species (ROS) production in cells treated with CDDP. The data reported clearly demonstrated that PON2 knockdown led to a significant reduction of cell proliferation and viability, as well as to an enhancement of A375 sensitivity to CDDP treatment. Moreover, enzyme downregulation was associated with an increase of ROS production in CDDP-treated cells. Although further analyses will be necessary to understand how PON2 could influence melanoma cell metabolism and phenotype, our results seem to suggest that the enzyme may serve as an interesting molecular target for effective melanoma treatment.
Collapse
Affiliation(s)
- Roberto Campagna
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (R.C.); (E.S.); (V.P.); (G.F.); (M.E.)
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy;
| | - Eleonora Salvolini
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (R.C.); (E.S.); (V.P.); (G.F.); (M.E.)
| | - Valentina Pozzi
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (R.C.); (E.S.); (V.P.); (G.F.); (M.E.)
| | - Elisa Molinelli
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (E.M.); (V.B.); (A.C.); (A.O.)
| | - Valerio Brisigotti
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (E.M.); (V.B.); (A.C.); (A.O.)
| | - Davide Sartini
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (R.C.); (E.S.); (V.P.); (G.F.); (M.E.)
- Correspondence: ; Tel.: +39-07-122-04676
| | - Anna Campanati
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (E.M.); (V.B.); (A.C.); (A.O.)
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (R.C.); (E.S.); (V.P.); (G.F.); (M.E.)
| | - Annamaria Offidani
- Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (E.M.); (V.B.); (A.C.); (A.O.)
| | - Monica Emanuelli
- Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; (R.C.); (E.S.); (V.P.); (G.F.); (M.E.)
- New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, 60131 Ancona, Italy
| |
Collapse
|
22
|
Blanc D, Racine V, Khalil A, Deloche M, Broyelle JA, Hammouamri I, Sinitambirivoutin E, Fiammante M, Verdier E, Besson T, Sadate A, Lederlin M, Laurent F, Chassagnon G, Ferretti G, Diascorn Y, Brillet PY, Cassagnes L, Caramella C, Loubet A, Abassebay N, Cuingnet P, Ohana M, Behr J, Ginzac A, Veyssiere H, Durando X, Bousaïd I, Lassau N, Brehant J. Artificial intelligence solution to classify pulmonary nodules on CT. Diagn Interv Imaging 2020; 101:803-810. [PMID: 33168496 DOI: 10.1016/j.diii.2020.10.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 10/12/2020] [Accepted: 10/13/2020] [Indexed: 12/20/2022]
Abstract
PURPOSE The purpose of this study was to create an algorithm to detect and classify pulmonary nodules in two categories based on their volume greater than 100 mm3 or not, using machine learning and deep learning techniques. MATERIALS AND METHOD The dataset used to train the model was provided by the organization team of the SFR (French Radiological Society) Data Challenge 2019. An asynchronous and parallel 3-stages pipeline was developed to process all the data (a data "pre-processing" stage; a "nodule detection" stage; a "classifier" stage). Lung segmentation was achieved using 3D U-NET algorithm; nodule detection was done using 3D Retina-UNET and classifier stage with a support vector machine algorithm on selected features. Performances were assessed using area under receiver operating characteristics curve (AUROC). RESULTS The pipeline showed good performance for pathological nodule detection and patient diagnosis. With the preparation dataset, an AUROC of 0.9058 (95% confidence interval [CI]: 0.8746-0.9362) was obtained, 87% yielding accuracy (95% CI: 84.83%-91.03%) for the "nodule detection" stage, corresponding to 86% specificity (95% CI: 82%-92%) and 89% sensitivity (95% CI: 84.83%-91.03%). CONCLUSION A fully functional pipeline using 3D U-NET, 3D Retina-UNET and classifier stage with a support vector machine algorithm was developed, resulting in high capabilities for pulmonary nodule classification.
Collapse
Affiliation(s)
- D Blanc
- QuantaCell, IRMB, Hôpital Saint-Eloi, 34090 Montpellier, France
| | - V Racine
- QuantaCell, IRMB, Hôpital Saint-Eloi, 34090 Montpellier, France
| | - A Khalil
- Department of Radiology, Neuroradiology unit, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat Claude Bernard, 75018 Paris, France; Université de Paris, 75010, Paris, France
| | - M Deloche
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | - J-A Broyelle
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | - I Hammouamri
- >IBM Cognitive Systems Lab, 34000 Montpellier, France
| | | | - M Fiammante
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - E Verdier
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - T Besson
- IBM Cognitive Systems France, 92270 Bois-Colombes, France
| | - A Sadate
- Department of Radiology and Medical Imaging, CHU Nîmes, University Montpellier, EA2415, 30029 Nîmes, France
| | - M Lederlin
- Department of Radiology, Hôpital Universitaire Pontchaillou, 35000 Rennes, France
| | - F Laurent
- Department of thoracic and cardiovascular Imaging, Respiratory Diseases Service, Respiratory Functional Exploration Service, Hôpital universitaire de Bordeaux, CIC 1401, 33600 Pessac, France
| | - G Chassagnon
- Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014, Paris, France & Université de Paris, 75006 Paris, France
| | - G Ferretti
- Department of Radiology and Medical Imaging, CHU Grenoble Alpes, 38700 Grenoble, France
| | - Y Diascorn
- Department of Radiology, Hôpital Universitaire Pasteur, Nice, France
| | - P-Y Brillet
- Inserm UMR 1272, Université Sorbonne Paris Nord, Assistance Publique-Hôpitaux de Paris, Department of Radiology, Hôpital Avicenne, 93430 Bobigny, France
| | - Lucie Cassagnes
- Department of radiology B, CHU Gabriel Montpied, 63003 Clermont-Ferrand, France
| | - C Caramella
- Department of Radiology, Institut Gustave Roussy, 94800 Villejuif, France
| | - A Loubet
- Department of Neuroradiology, Hôpital Gui-de-Chauliac, CHRU de Montpellier, 34000 Montpellier, France
| | - N Abassebay
- Department of Radiology, CH Douai, 59507 Douai, France
| | - P Cuingnet
- Department of Radiology, CH Douai, 59507 Douai, France
| | - M Ohana
- Department of Radiology, Nouvel Hôpital Civil, 67000 Strasbourg, France
| | - J Behr
- Department of Radiology, CHRU de Jean-Minjoz Besançon, 25030 Besançon, France
| | - A Ginzac
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France
| | - H Veyssiere
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France
| | - X Durando
- Clinical Research Unit, Clinical Research and Innovation Delegation, Centre de Lutte contre le Cancer, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 1, France; Université Clermont Auvergne,INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Clinical Investigation Center, UMR501, 63011 Clermont-Ferrand, France; Department of Medical Oncology, Centre Jean Perrin, 63011 Clermont-Ferrand, France
| | - I Bousaïd
- Digital Transformation and Information Systems Division, Gustave Roussy, 94800 Villejuif, France
| | - N Lassau
- Multimodal Biomedical Imaging Laboratory Paris-Saclay, BIOMAPS, UMR 1281, Université Paris-Saclay, Inserm, CNRS, CEA, Department of Radiology, Institut Gustave Roussy, 94800, Villejuif, France
| | - J Brehant
- Department of Radiology, Centre Jean Perrin, 63011 Clermont-Ferrand, France.
| |
Collapse
|
23
|
Cianfruglia L, Morresi C, Bacchetti T, Armeni T, Ferretti G. Protection of Polyphenols against Glyco-Oxidative Stress: Involvement of Glyoxalase Pathway. Antioxidants (Basel) 2020; 9:antiox9101006. [PMID: 33081239 PMCID: PMC7602851 DOI: 10.3390/antiox9101006] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 10/10/2020] [Accepted: 10/14/2020] [Indexed: 02/07/2023] Open
Abstract
Chronic high glucose (HG) exposure increases methylglyoxal (MGO)-derived advanced glycation end-products (AGEs) and is involved in the onset of pathological conditions, such as diabetes, atherosclerosis and chronic-degenerative diseases. Under physiologic conditions the harmful effects of MGO are contrasted by glyoxalase system that is implicated in the detoxification of Reactive Carbonyl Species (RCS) and maintain the homeostasis of the redox environment of the cell. Polyphenols are the most abundant antioxidants in the diet and present various health benefits. Aims of the study were to investigate the effects of HG-chronic exposure on glyco-oxidation and glyoxalase system in intestinal cells, using CaCo-2 cells. Moreover, we studied the effect of apple polyphenols on glyco-oxidative stress. Our data demonstrated that HG-treatment triggers glyco-oxidation stress with a significant increase in intracellular Reactive Oxygen Species (ROS), lipid peroxidation, AGEs, and increase of Glyoxalase I (GlxI) activity. On the contrary, Glyoxalase II (GlxII) activity was lower in HG-treated cells. We demonstrate that apple polyphenols exert a protective effect against oxidative stress and dicarbonyl stress. The increase of total antioxidant capacity and glutathione (GSH) levels in HG-treated cells in the presence of apple polyphenols was associated with a decrease of GlxI activity.
Collapse
Affiliation(s)
- Laura Cianfruglia
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (G.F.)
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy;
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy;
- Correspondence: (T.B.); (T.A.)
| | - Tatiana Armeni
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (G.F.)
- Correspondence: (T.B.); (T.A.)
| | - Gianna Ferretti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (G.F.)
| |
Collapse
|
24
|
Fabi A, Ferretti G, Cognetti F. How to restructure the management of Italian oncological patients during and after COVID-19 pandemic? Eur Rev Med Pharmacol Sci 2020; 24:6478-6479. [PMID: 32633331 DOI: 10.26355/eurrev_202006_21626] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A Fabi
- Division of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
| | | | | |
Collapse
|
25
|
Charara S, Ghelfi J, Chirica M, Thony F, Ferretti G. Embolisation of left-gastric artery pseudoaneurysm with artery to hepatic vein fistula using a transjugular approach. Diagn Interv Imaging 2020; 101:257-258. [DOI: 10.1016/j.diii.2019.11.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 11/06/2019] [Accepted: 11/10/2019] [Indexed: 10/25/2022]
|
26
|
Fumarola S, Cecati M, Sartini D, Ferretti G, Milanese G, Galosi AB, Pozzi V, Campagna R, Morresi C, Emanuelli M, Bacchetti T. Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression. Antioxidants (Basel) 2020; 9:antiox9020175. [PMID: 32093309 PMCID: PMC7070528 DOI: 10.3390/antiox9020175] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 02/17/2020] [Accepted: 02/18/2020] [Indexed: 12/12/2022] Open
Abstract
The goal of the current study was to identify potential roles of paraoxonase-2 in bladder carcinogenesis. T24 bladder cancer cells were transfected with plasmids inducing paraoxonase-2 silencing or overexpression. Upon the selection of clones stably down- or upregulating paraoxonase-2, cell proliferation, migration, and the production of reactive oxygen species were evaluated, before and after treatment with cisplatin and gemcitabine, used alone or in combination. The activity levels of both caspase-3 and caspase-8 were also analyzed. shRNA-mediated gene silencing and the overexpression of paraoxonase-2 revealed that the enzyme was able to promote both the proliferation and migration of T24 cells. Moreover, the knockdown of paraoxonase-2 was significantly associated with a reduced cell viability of T24 cells treated with chemotherapeutic drugs and led to both an increase of reactive oxygen species production and caspase-3 and caspase-8 activation. Conversely, under treatment with anti-neoplastic compounds, a higher proliferative capacity was found in T24 cells overexpressing paraoxonase-2 compared with controls. In addition, upon enzyme upregulation, both the production of reactive oxygen species and activation of caspase-3 and caspase-8 were reduced. Although further analyses will be required to fully understand the involvement of paraoxonase-2 in bladder tumorigenesis and in mechanisms leading to the development of chemoresistance, the data reported in this study seem to demonstrate that the enzyme could exert a great impact on tumor progression and susceptibility to chemotherapy, thus suggesting paraoxonase-2 as a novel and interesting molecular target for effective bladder cancer treatment.
Collapse
Affiliation(s)
- Stefania Fumarola
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Monia Cecati
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Davide Sartini
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Giulio Milanese
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Andrea Benedetto Galosi
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Valentina Pozzi
- New York-Marche Structural Biology Center, Polytechnic University of Marche, 60131 Ancona, Italy;
| | - Roberto Campagna
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy (T.B.)
| | - Monica Emanuelli
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (S.F.); (M.C.); (D.S.); (G.F.); (G.M.); (A.B.G.); (R.C.)
- New York-Marche Structural Biology Center, Polytechnic University of Marche, 60131 Ancona, Italy;
- Correspondence: ; Tel.: +390712204681; Fax: +390712204398
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy (T.B.)
| |
Collapse
|
27
|
Bacchetti T, Morresi C, Bellachioma L, Ferretti G. Antioxidant and Pro-Oxidant Properties of Carthamus Tinctorius, Hydroxy Safflor Yellow A, and Safflor Yellow A. Antioxidants (Basel) 2020; 9:antiox9020119. [PMID: 32013224 PMCID: PMC7070856 DOI: 10.3390/antiox9020119] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 01/22/2020] [Accepted: 01/23/2020] [Indexed: 12/30/2022] Open
Abstract
(1) Carthamus Tinctorius L. (safflower) is extensively used in traditional herbal medicine. (2) The aim of this study was to investigate the bioactive properties of polyphenol extracts from flowers of Carthamus Tinctorius (CT) cultivated in Italy. We also evaluated the properties of two bioactive water-soluble flavonoid compounds, hydroxy safflor yellow A (HSYA) and safflor yellow A (SYA), contained in Carthamus Tinctorius petals. (3) The total polyphenol content was 3.5 ± 0.2 g gallic acid equivalent (GAE)/100 g, flavonoids content was 330 ± 23 mg catechin equivalent (CE)/100 g in the flowers. The extract showed a high antioxidant activity evaluated by oxygen radical absorbance capacity (ORAC) and 2-diphenyl-1-picrylhydrazyl (DPPH) radical-scavenging assays. In addition, flower extract, SYA, and HSYA were able to reduce the susceptibility of low-density lipoprotein to copper-induced lipid peroxidation. In order to investigate the bioactive properties of flower extract, SYA, and HSYA we also studied their modulatory effect of oxidative stress on human dermal fibroblasts (HuDe) oxidized by tert-butyl hydroperoxide (t-BOOH). The CT extract at concentrations ranging from 0.01–20 μg GAE/mL of polyphenols, exerted a protective effect against t-BOOH triggered oxidative stress. At higher concentration the extract exerted a pro-oxidant effect. Similar results have been obtained using HSYA and SYA. (4) These results demonstrate a biphasic effect exerted by HSYA, SYA, and flower extracts on oxidative stress.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (T.B.); (C.M.); (L.B.)
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (T.B.); (C.M.); (L.B.)
| | - Luisa Bellachioma
- Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy; (T.B.); (C.M.); (L.B.)
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
- Correspondence: ; Tel.: +39-071-220-4968
| |
Collapse
|
28
|
Morresi C, Cianfruglia L, Sartini D, Cecati M, Fumarola S, Emanuelli M, Armeni T, Ferretti G, Bacchetti T. Effect of High Glucose-Induced Oxidative Stress on Paraoxonase 2 Expression and Activity in Caco-2 Cells. Cells 2019; 8:cells8121616. [PMID: 31835890 PMCID: PMC6953021 DOI: 10.3390/cells8121616] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 12/04/2019] [Accepted: 12/05/2019] [Indexed: 01/14/2023] Open
Abstract
(1) Background: Hyperglycemia leads to several biochemical and physiological consequences, such as the generation of advanced glycation end products (AGEs) and reactive oxygen species (ROS), which are involved in the development of several human diseases. Intestinal cells are continuously exposed to pro-oxidants and lipid peroxidation products from ingested foods, and also to glyco-oxidative damage. It has been reported that free radical generation may be linked to the development of inflammation-related gastrointestinal diseases. (2) Methods: The effects of high glucose (HG) treatment (50 mM) were assessed in terms of free radical production, lipid peroxidation, and AGEs formation. Furthermore, the expression and the antiapoptotic and antioxidant activity of the paraoxonase-2 (PON2) enzyme in intestinal cells has been investigated. (3) Results: Caco-2 cells treated with media supplied with high glucose (HG) (50 mM) showed, with respect to physiological glucose concentration (25 mM), an increase in ROS production, lipid peroxidation, and AGEs formation. Moreover, a lower PON2 expression and activity in HG-treated cells was related to activation of the apoptotic pathways. (4) Conclusions: Our results demonstrated that high glucose concentrations triggered glyco-oxidative stress in intestinal cells; the downregulation of PON2 could result in a higher oxidative stress and might contribute to intestinal dysfunction.
Collapse
Affiliation(s)
- Camilla Morresi
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (C.M.); (M.C.); (T.B.)
| | - Laura Cianfruglia
- Department of Clinical Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (D.S.); (S.F.); (M.E.)
| | - Davide Sartini
- Department of Clinical Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (D.S.); (S.F.); (M.E.)
| | - Monia Cecati
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (C.M.); (M.C.); (T.B.)
| | - Stefania Fumarola
- Department of Clinical Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (D.S.); (S.F.); (M.E.)
| | - Monica Emanuelli
- Department of Clinical Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (D.S.); (S.F.); (M.E.)
| | - Tatiana Armeni
- Department of Clinical Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (D.S.); (S.F.); (M.E.)
- Correspondence: (T.A.); (G.F.); Tel.: +39-07-1220-4376 (T.A.); +39-07-1220-4968 (G.F.)
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (L.C.); (D.S.); (S.F.); (M.E.)
- Correspondence: (T.A.); (G.F.); Tel.: +39-07-1220-4376 (T.A.); +39-07-1220-4968 (G.F.)
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, 60131 Ancona, Italy; (C.M.); (M.C.); (T.B.)
| |
Collapse
|
29
|
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol 2019; 30:1985-1991. [PMID: 31584608 DOI: 10.1093/annonc/mdz407] [Citation(s) in RCA: 111] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed approvals. Efficacy and safety was then assessed using a two-stage Simon phase II trial design. When the study design was designed, crizotinib was approved only as monotherapy for adults with anaplastic lymphoma kinase plus non-small-cell lung cancers (NSCLC). PATIENTS AND METHODS Advanced NSCLC patients with c-MET ≥6 copies, c-MET-mutated, or ROS-1-translocated tumours were enrolled in one of the three cohorts. Patients were treated with crizotinib 250 mg twice daily. Efficacy was assessed using the objective response rate (ORR) after two cycles of crizotinib as primary outcome. Secondary outcomes included disease control rate at four cycles, best ORR, progression-free survival, overall survival, and drug tolerance. RESULTS From August 2013 to March 2018, 5606 patients had their tumour tested for crizotinib targeted molecular alterations: 252 patients had c-MET ≥6 copies, 74 c-MET-mutation, and 78 ROS-1-translocated tumour. Finally, 25 patients in the c-MET ≥6 copies cohort, 28 in the c-MET-mutation cohort, and 37 in the ROS-1-translocation cohort were treated in the phase II trial. The ORR was 16% in the c-MET ≥6 copies cohort, 10.7% in the mutated, and 47.2% in the ROS-1 cohort. The best ORR during treatment was 32% in the c-MET-≥6 copies cohort, 36% in the c-MET-mutated, and 69.4% in the ROS-1-translocation cohort. Safety data were consistent with that previously reported. CONCLUSIONS Crizotinib activity in patients with ROS1-translocated tumours was confirmed. In the c-MET-mutation and c-MET ≥6 copies cohorts, despite insufficient ORR after two cycles of crizotinib, there are signs of late response not sufficient to justify the development of crizotinib in this indication. The continued targeting of c-MET with innovative therapies appears justified. CLINICAL TRIAL NUMBER NCT02034981.
Collapse
Affiliation(s)
- D Moro-Sibilot
- Thoracic Oncology Unit, Grenoble-Alpes University Hospital, Grenoble; Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris.
| | - N Cozic
- Department of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, INSERM U1018, ESP, Paris-Saclay and Paris-Sud Universities, Villejuif
| | - M Pérol
- Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon
| | - J Mazières
- Pneumology Department, Toulouse University Hospital and Paul Sabatier University, Toulouse
| | - J Otto
- Department of Medicine, Antoine Lacassagne Cancer Centre, Nice
| | - P J Souquet
- Department of Pneumology and Thoracic Oncology, Lyon Sud Hospital Center, Hospices Civils de Lyon, Pierre Bénite
| | - R Bahleda
- Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif
| | - M Wislez
- Pneumology Department, Tenon Hospital, AP-HP and "Pierre and Marie Curie" University, Paris
| | - G Zalcman
- Thoracic Oncology Department-CIC INSERM 1425, Bichat University Hospital, AP-HP, Paris; Paris-Diderot University, Paris
| | | | - F Barlési
- Multidisciplinary Oncology & Therapeutic Innovations Department, APHM and Aix Marseille University, INSERM, CNRS, CRCM, Marseille
| | - B Mennecier
- Pneumology Department, Strasbourg University Hospital, Strasbourg
| | - I Monnet
- Pneumology Department, CHIC Creteil, Créteil
| | - R Sabatier
- Department of Medical Oncology, Inserm 1068, CNRS UMR7258, CRCM, Paoli-Calmettes Institute and Aix-Marseille University, Marseille
| | - S Bota
- Pneumology Department, Charles Nicolle Hospital, Rouen University Hospital, Rouen
| | - C Dubos
- Pneumology Department, François Baclesse Cancer Centre, Caen
| | - V Verriele
- Anatomy and Pathological Cytologies Department, Paul Papin Cancer Centre, ICO, Angers
| | - V Haddad
- Department of Tumour Biology, Léon Bérard Cancer Centre, Lyon
| | - G Ferretti
- Radiology and Medical Imaging Department, Grenoble-Alpes University Hospital, Grenoble
| | - A Cortot
- Department of Thoracic Oncology, Lille University Hospital and University of Lille, Lille
| | - F De Fraipont
- Molecular Genetic Unit: Hereditary Diseases and Oncology, Grenoble-Alpes University Hospital, Grenoble
| | - M Jimenez
- Research and Development UNICANCER, Paris
| | | | - G Vassal
- Clinical Research Division, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
30
|
Benet J, Toffart A, Frey G, Chollier T, Ruckly S, Villa J, Emprou C, Pinsolle J, Dumas I, Guillem P, Ferretti G, Moro-Sibilot D, Levra MG. P2.18-10 Importance of the Multidisciplinary Tumor Board in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Bacchetti T, Simonetti O, Ricotti F, Offidani A, Ferretti G. Plasma oxidation status and antioxidant capacity in psoriatic children. Arch Dermatol Res 2019; 312:33-39. [PMID: 31531730 DOI: 10.1007/s00403-019-01976-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 07/16/2019] [Accepted: 08/30/2019] [Indexed: 12/18/2022]
Abstract
Psoriasis, a chronic inflammatory skin disease, is associated with oxidative stress of serum lipoproteins. In psoriatic children we evaluated the activity and levels of myeloperoxidase, the activity of paraoxonase-1 (PON1) and biochemical markers of lipid peroxidation, to investigate wether an unbalance between oxidant-antioxidants occurs very early in psoriasis. A total of 52 patients affected by psoriasis and 48 sex-age-matched healthy controls were enrolled. Serum MPO levels were measured using ELISA method. MPO and PON1 activities (paraoxonase, arylesterase and lactonase) were evaluated by spectroscopic methods. Our results demonstrated a significant increase of MPO levels and activity in psoriatic subjects. PON1 activities were found to be significantly decreased. A positive correlation has been established between the MPO/PON1 ratio and levels of lipid peroxides in all psoriatic patients. These results suggest that an unbalance between MPO and PON1 can reflect in higher oxidative stress in serum lipoproteins.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences- Biochemistry, Università Politecnica delle Marche, 60100, Ancona, Italy
| | - Oriana Simonetti
- Department of Clinical and Molecular Sciences- Dermatology, Università Politecnica delle Marche, 60100, Ancona, Italy.
| | - Francesca Ricotti
- Department of Clinical and Molecular Sciences- Dermatology, Università Politecnica delle Marche, 60100, Ancona, Italy
| | - Annamaria Offidani
- Department of Clinical and Molecular Sciences- Dermatology, Università Politecnica delle Marche, 60100, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Experimental Science and Odontostomatology- Biochemistry, Università Politecnica delle Marche, 60100, Ancona, Italy
| |
Collapse
|
32
|
Bacchetti T, Morresi C, Vignini A, Tiano L, Orlando P, Montik N, Ciavattini A, Ferretti G. HDL functionality in follicular fluid in normal-weight and obese women undergoing assisted reproductive treatment. J Assist Reprod Genet 2019; 36:1657-1664. [PMID: 31338723 PMCID: PMC6708027 DOI: 10.1007/s10815-019-01523-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 07/08/2019] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE High-density lipoproteins (HDL) exert pleiotropic roles in follicular fluid (FF). Previous studies have reported a relationship between obesity, infertility, and systemic oxidative stress. The aim of our study was to investigate for the first time the HDL functional properties in FF in obesity. METHODS In this observational study, overweight/obese (n = 20) and normal-weight women (n = 38) undergoing assisted reproductive technology were included. Compositional properties and biochemical marker of functionality (HDL oxidation rate), HDL-associated antioxidants (paraoxonase-1 activities and CoQ10 content), and lipid hydroperoxide levels were evaluated in FF from normal-weight and overweight/obese women. Correlations between biochemical parameters and indices for oocyte and embryo quality were studied. RESULTS FF-HDL obtained from overweight/obese women are characterized by high intrinsic ability to be oxidized compared with FF-HDL from normal-weight women. These alterations are associated with lower activities of paraoxonase-1 (PON1), higher levels of lipid peroxidation, and a lower total antioxidant capacity in FF. Moreover, an association between PON1 activity and FF-HDL oxidation and clinical parameter of oocyte quality was observed. CONCLUSION Our data suggest that the quality of FF-HDL is important determinant for oocyte quality. Therefore, targeting FF-HDL functionality, in addition to FF-HDL-C levels, may represent a promising and interesting biomarker for reproductive outcomes.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy.
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Arianna Vignini
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Ancona, Italy
| | - Luca Tiano
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Patrick Orlando
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Nina Montik
- Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, Ancona, Italy
| | - Andrea Ciavattini
- Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Polytechnic University of Marche, Ancona, Italy
| |
Collapse
|
33
|
Nelson S, Milgrom P, Albert JM, Selvaraj D, Cunha-Cruz J, Curtan S, Copeland T, Heima M, Rothen M, Beck G, Ferretti G, Riedy C. Randomized Trial Based on the Common-Sense Model of Self-regulation to Increase Child Dental Visits. JDR Clin Trans Res 2019; 4:323-332. [PMID: 30931720 DOI: 10.1177/2380084419830662] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION School screening and the note home (pinned to a backpack) informing parents/caregivers that their child needs to see a dentist have not been effective. OBJECTIVES The Family Access to a Dentist Study (FADS) evaluated the effectiveness of school interventions based on the common-sense model of self-regulation (CSM) among K-4 children needing restorative treatment. METHODS FADS was a multisite double-blind randomized controlled trial with 5 arms. FADS tested a CSM-driven referral letter and dental information guide (DIG) to move caregivers from inaccurate to accurate perceptions of dental caries. Six school districts from Ohio and Washington (14 schools) participated in school years 2015 to 2016 and 2016 to 2017. A total of 611 caregivers were randomized, and 86% (n = 597 children) completed the exit examination. The primary outcome was receipt of care based on a change in oral health status determined clinically within 1 school year. RESULTS In accordance with our primary aims, 5 arms were collapsed into 3: CSM letter and reduced CSM letter (combined), CSM letter + DIG and reduced CSM letter + reduced DIG (combined), and standard letter. Among all sites, 39.7% received restorative care (237 of 597). Combined analysis of sites revealed that the CSM referral letter (with and without the DIG) did not increase dental visits when compared with the standard letter. However, for combined sites (East Cleveland, Ohio; Washington), the CSM + DIG increased dental visits when compared with standard letter in univariate analysis (51.3% vs. 40.9%), indicating 1.6-times increased odds of a dental visit (95% CI, 0.97 to 2.58) after imputation and adjustment for covariates. The CSM + DIG group had 1.9-times increased odds (95% CI, 1.21 to 3.08) of care when compared the CSM letter alone. CONCLUSION A CSM-driven approach to informing caregivers of the chronic nature of caries with resources in an illustrative manner can increase the benefit of school oral health screening (ClinicalTrials.gov NCT02395120). KNOWLEDGE TRANSFER STATEMENT A school dental referral (note home) that tells a parent that the child has cavities has not been effective. In this trial, a referral based on the common-sense model of self-regulation increased follow-up care for children with restorative needs.
Collapse
Affiliation(s)
- S Nelson
- Department of Community Dentistry, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - P Milgrom
- Department of Oral Health Sciences, University of Washington, Seattle, WA, USA
| | - J M Albert
- Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - D Selvaraj
- Department of Community Dentistry, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - J Cunha-Cruz
- Department of Oral Health Sciences, University of Washington, Seattle, WA, USA
| | - S Curtan
- Department of Community Dentistry, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - T Copeland
- Department of Community Dentistry, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - M Heima
- Department of Pediatric Dentistry, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - M Rothen
- Department of Oral Health Sciences, University of Washington, Seattle, WA, USA
| | - G Beck
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
| | - G Ferretti
- Department of Pediatric Dentistry, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, USA
| | - C Riedy
- Department of Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Boston, MA, USA
| |
Collapse
|
34
|
Rossi V, Giannarelli D, Berchialla P, Montemurro F, Ferretti G, Nistico' C, Vigna L, Cognetti F, Fabi A. Abstract P2-08-34: The network metanalysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials: Progression free survival (PFS) benefit from first-line endocrine-based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The three classes of Cycline Dependend Kinase (CDK) 4/6 inhibitors, Palbociclib (P), Ribociclib (R) and Abemaciclib (A), in combination with non-Steroidal Aromatase Inhibitors (nSAIs) showed improvement on Progression Free Survival (PFS) in patients with HR+/HER2- MBC compared to AIs monotherapy.
Fulvestrant (F) also showed a PFS benefit over AIs in first-line setting of endocrine naive patients (pts) which was even greater in pts whithout visceral disease.
The absence of direct comparison between F and CDK 4/6 combination therapies and their less favorable toxicity profile generated great interest in the identification of a specific subgroup of pts based on clinical and pathological factors for decision-making in the use of endocrine monotherapy.
This analysis combines data from six randomized phase III trials investigating the role of endocrine-based therapies in the first-line setting of HR+/HER2- MBC to identify clinical factors in the choice among available drugs.
Methods
A Bayesian network meta-analysis was carried out for PFS; Hazard Ratio (HR) and 95% CI were reported. Potential treatment effect modifying covariates were investigated using sub-group analysis, stratifying by age, ECOG, ethnicity, prior chemotherapy or endocrine therapy exposure, measurable disease at the time of metastasis occurrence, visceral or bone only disease, time from the initial diagnosis of breast cancer to the metastasis onset. Data analysis was performed using R Statistical Software version 3.5.0
Results
In the absence of direct comparison between CDK 4/6 inhibitors + nAIs and F endocrine-based therapies, all these therapeutic options resulted in significant PFS benefit compared to nAIs monotherapy (HR: 0.74; 95% CI 0.67-0.80). However, among the three classes of CDK 4/6 inhibitors and F a significant longer PFS was observed according to some clinical-pathological factors as followed reported: from P + nAIs in “bone only” disease (HR 0.47; CI 0.25-0.86); from A + nAis in “de novo” subgroup (HR 0.60; CI 0.37-0.97), in “Asian” population (HR 0.37; CI 0.16-0.85) and “non visceral” disease (HR 0.48 CI 0.25-0.89); from R + nAIs in “de novo” subgroup (HR 0.55; CI 0.32-0.95) and in “visceral” disease (HR 0.66 CI 0.45-0.96); from all the three combination strategies (A, P and R) in “prior endocrine” exposure subgroup (HR 0.47 CI 0.25-0.87; HR 0.60 CI 0.45-0.80; HR 0.64 CI 0.41-1.0, respectively). Even though no significant PFS benefit was observed in the remaining subgroups, combined CDK 4/6 strategies appeared more effective than F according to relative HR.
Conclusions
CDK 4/6 inhibitors endocrine-based therapies as first-line treatment for postmenopausal women with HR+/HER2- MBC showed PFS improvement, regardless of prognostic subgroup and additionally advantage was emerged by indirect comparison with F. Further direct comparative studies are needed to explore greater benefits from different therapeutic options.
Citation Format: Rossi V, Giannarelli D, Berchialla P, Montemurro F, Ferretti G, Nistico' C, Vigna L, Cognetti F, Fabi A. The network metanalysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials: Progression free survival (PFS) benefit from first-line endocrine-based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-34.
Collapse
Affiliation(s)
- V Rossi
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - D Giannarelli
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - P Berchialla
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - F Montemurro
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - G Ferretti
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - C Nistico'
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - L Vigna
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - F Cognetti
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| | - A Fabi
- Breast Tumour Unit, S.Camillo-Forlanini Hospital of Rome, Rome, Italy; Istituto Regina Elena of Rome, Rome, Italy; University of Turin, Turin, Italy; Investigative Clinical Oncology (INCO)-Fondazione del Piemonte per l'Oncologia, Candiolo, Turin, Italy
| |
Collapse
|
35
|
Bordicchia M, Spannella F, Ferretti G, Bacchetti T, Vignini A, Di Pentima C, Mazzanti L, Sarzani R. PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides. Int J Mol Sci 2019; 20:ijms20020245. [PMID: 30634533 PMCID: PMC6358804 DOI: 10.3390/ijms20020245] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 12/05/2018] [Accepted: 01/04/2019] [Indexed: 01/14/2023] Open
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to and degrades the low-density lipoprotein receptor (LDLR), contributing to hypercholesterolemia. Adipose tissue plays a role in lipoprotein metabolism, but there are almost no data about PCSK9 and LDLR regulation in human adipocytes. We studied PCSK9 and LDLR regulation by insulin, atrial natriuretic peptide (ANP, a potent lipolytic agonist that antagonizes insulin), and LDL in visceral adipose tissue (VAT) and in human cultured adipocytes. PCSK9 was expressed in VAT and its expression was positively correlated with body mass index (BMI). Both intracellular mature and secreted PCSK9 were abundant in cultured human adipocytes. Insulin induced PCSK9, LDLR, and sterol-regulatory element-binding protein-1c (SREBP-1c) and -2 expression (SREBP-2). ANP reduced insulin-induced PCSK9, especially in the context of a medium simulating hyperglycemia. Human LDL induced both mature and secreted PCSK9 and reduced LDLR. ANP indirectly blocked the LDLR degradation, reducing the positive effect of LDL on PCSK9. In conclusion, PCSK9 is expressed in human adipocytes. When the expression of PCSK9 is induced, LDLR is reduced through the PCSK9-mediated degradation. On the contrary, when the induction of PCSK9 by insulin and LDL is partially blocked by ANP, the LDLR degradation is reduced. This suggests that NPs could be able to control LDLR levels, preventing PCSK9 overexpression.
Collapse
Affiliation(s)
- Marica Bordicchia
- Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", 60126 Ancona, Italy.
| | - Francesco Spannella
- Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", 60126 Ancona, Italy.
- Internal Medicine and Geriatrics, "Hypertension Excellence Centre" of the European Society of Hypertension, IRCCS-INRCA, 60127 Ancona, Italy.
| | - Gianna Ferretti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, School of Nutrition, University "Politecnica delle Marche", 60126 Ancona, Italy.
| | - Tiziana Bacchetti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, School of Nutrition, University "Politecnica delle Marche", 60126 Ancona, Italy.
| | - Arianna Vignini
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, School of Nutrition, University "Politecnica delle Marche", 60126 Ancona, Italy.
| | - Chiara Di Pentima
- Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", 60126 Ancona, Italy.
- Internal Medicine and Geriatrics, "Hypertension Excellence Centre" of the European Society of Hypertension, IRCCS-INRCA, 60127 Ancona, Italy.
| | - Laura Mazzanti
- Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, School of Nutrition, University "Politecnica delle Marche", 60126 Ancona, Italy.
| | - Riccardo Sarzani
- Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", 60126 Ancona, Italy.
- Internal Medicine and Geriatrics, "Hypertension Excellence Centre" of the European Society of Hypertension, IRCCS-INRCA, 60127 Ancona, Italy.
| |
Collapse
|
36
|
Abstract
Products obtained using 100% legume flours (pea, red lentil, chickpea, grass pea) contain elevated levels of healthy functional components and have a low glycaemic index.
Collapse
Affiliation(s)
- Imma Turco
- Department of Clinical Experimental Science and Odontostomatology
- Polytechnic University of Marche
- 60131 Ancona
- Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences
- Polytechnic University of Marche
- 60131 Ancona
- Italy
| | - Camilla Morresi
- Department of Life and Environmental Sciences
- Polytechnic University of Marche
- 60131 Ancona
- Italy
| | - Lucia Padalino
- University of Foggia
- Services Center of Applied Research
- Foggia
- Italy
| | - Gianna Ferretti
- Department of Clinical Experimental Science and Odontostomatology
- Polytechnic University of Marche
- 60131 Ancona
- Italy
- Research Center of Health Education and Health Promotion
| |
Collapse
|
37
|
Morresi C, Cianfruglia L, Armeni T, Mancini F, Tenore GC, D’Urso E, Micheletti A, Ferretti G, Bacchetti T. Inside Back Cover Image, Volume 42, Issue 6. J Food Biochem 2018. [DOI: 10.1111/jfbc.12754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Bacchetti T, Turco I, Urbano A, Morresi C, Ferretti G. Relationship of fruit and vegetable intake to dietary antioxidant capacity and markers of oxidative stress: A sex-related study. Nutrition 2018; 61:164-172. [PMID: 30716560 DOI: 10.1016/j.nut.2018.10.034] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Revised: 09/25/2018] [Accepted: 10/25/2018] [Indexed: 12/12/2022]
Abstract
OBJECTIVES Oxidative stress contributes to the development of chronic diseases. Fruits and vegetables contain several phytonutrients (carotenoids, polyphenols) that exert antioxidant effects. The aim of this study was to investigate sex differences in fruit and vegetable intake, and the relationship to plasma levels of carotenoids as well as to total antioxidant capacity (pTAC). We studied also sex differences in the relationship between fruit and vegetables intake and plasma levels of lipid hydroperoxides, as well as of oxidized low-density lipoprotein (ox-LDL). METHODS This study included 83 healthy adults (35 men and 48 women, mean age 40 ± 10 y). Dietary intake of carotenoids and total antioxidant capacity (dTAC) were evaluated on the basis of a 15-d food frequency questionnaire. Plasma levels of β-carotene, lutein, and pTAC were studied. Moreover, levels of plasma lipid hydroperoxides and ox-LDL were evaluated using the ferrous oxidation-xylenol orange 2 (FOX2) assay and a monoclonal antibody-based enzyme-linked immunosorbent assay procedure, respectively. RESULTS Dietary habits were sex-related with a higher intake of fruits and vegetables (P < 0.05) and β-carotene (P < 0.001) in women than in men. Mean values of plasma lutein and β-carotene were higher in women than in men. Mean values of ox-LDL and lipid hydroperoxides were higher in men than in women (P < 0.05). Significant negative correlations were established between the individual values of ox-LDL and the levels of lutein versus β-carotene and versus pTAC values in plasma in both groups. Individuals belonging to the tertile with the highest daily intake of fruits and vegetables or the highest daily dTAC showed the lowest levels of plasma ox-LDL. In each category, sex-related differences were observed with men showing higher levels of ox-LDL than women. Moreover, lower levels of plasma β-carotene were observed in men in each tertile of daily intake of fruits and vegetables compared with females. CONCLUSIONS Based on the data obtained, we confirm that high fruit and vegetable consumption exerts a positive effect on antioxidant defenses and decreases oxidative damage of plasma lipoproteins for both sexes. The results suggest that the protective effect can be found to a higher extent in women than in men. Sex-based differences are apparent in many chronic diseases. Thus, a higher consumption of antioxidant-rich fruits and vegetables should be recommended in efforts to prevent diseases in which sex-related differences in oxidative stress play a considerable role.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, Ancona, Italy
| | - Imma Turco
- Department of Clinical Experimental Science and Odontostomatology, Polytechnic University of Marche, Ancona, Italy
| | - Antonietta Urbano
- Department of Clinical Experimental Science and Odontostomatology, Polytechnic University of Marche, Ancona, Italy
| | - Camilla Morresi
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Via Brecce Bianche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Experimental Science and Odontostomatology, Polytechnic University of Marche, Ancona, Italy; Research Center of Health Education and Health Promotion, Polytechnic University of Marche, Ancona, Italy.
| |
Collapse
|
39
|
Mazières J, Montané L, Barlesi F, Quantin X, Trédaniel J, Le Treut J, Avrillon V, Lavolé A, Westeel V, Orsini Piocelle F, Pichon E, Thiberville L, Borel C, Renault P, Jaffro M, Collot S, Ferretti G, Legrand F, Mahier Ait Oukhatar C, Blay J. Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Mazieres J, Montané L, Barlesi F, Coudert B, Souquet P, Otto J, Gervais R, Moro-Sibilot D, Monnet I, Brain E, Huillard O, Quéré G, Debieuvre D, Fabre E, Jaffro M, Collot S, Ferretti G, Tiffon C, Mahier - Ait Oukhatar C, Blay J. OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.302] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Rossi V, Giannarelli D, Berchialla P, Nisticò C, Ferretti G, Gasparro S, Malaguti P, Russillo M, Catania G, Vigna L, Mancusi R, Cognetti F, Fabi A. Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Morresi C, Cianfruglia L, Armeni T, Mancini F, Tenore GC, D’Urso E, Micheletti A, Ferretti G, Bacchetti T. Polyphenolic compounds and nutraceutical properties of old and new apple cultivars. J Food Biochem 2018. [DOI: 10.1111/jfbc.12641] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Camilla Morresi
- Department of Life and Environmental Sciences Polytechnic University of Marche Ancona Italy
| | - Laura Cianfruglia
- Department of Clinical Experimental Science and Odontostomatology Polytechnic University of Marche Ancona Italy
| | - Tatiana Armeni
- Department of Clinical Experimental Science and Odontostomatology Polytechnic University of Marche Ancona Italy
| | - Francesca Mancini
- Department of Clinical Experimental Science and Odontostomatology Polytechnic University of Marche Ancona Italy
| | - Gian Carlo Tenore
- Department of Pharmacy University of Naples Federico II Napoli Italy
| | - Emanuela D’Urso
- Department of Pharmacy University of Naples Federico II Napoli Italy
| | - Ambra Micheletti
- Agency for Agro‐food Sector Services of the Marche Region (ASSAM) Osimo Italy
| | - Gianna Ferretti
- Department of Pharmacy University of Naples Federico II Napoli Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences Polytechnic University of Marche Ancona Italy
| |
Collapse
|
43
|
Marini E, Magi G, Ferretti G, Bacchetti T, Giuliani A, Pugnaloni A, Rippo MR, Facinelli B. Attenuation of Listeria monocytogenes Virulence by Cannabis sativa L. Essential Oil. Front Cell Infect Microbiol 2018; 8:293. [PMID: 30186775 PMCID: PMC6113369 DOI: 10.3389/fcimb.2018.00293] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 07/31/2018] [Indexed: 12/15/2022] Open
Abstract
Anti-virulence strategies are being explored as a novel approach to combat pathogens. Such strategies include inhibition of surface adhesion, tissue invasion, toxin production, and/or interference with the gene regulation of other virulence traits. Listeria monocytogenes, the causative agent of listeriosis, is a facultative intracellular food pathogen characterized by a wide distribution in the environment. Its ability to persist within biofilms and to develop resistance to sanitizers is the cause of significant problems in food processing plants and of steep costs for the food industry. In humans, the treatment of listeriosis is hampered by the intracellular location of listeriae and the poor intracellular penetration of some antibiotics. Eleven L. monocytogenes isolates from patients who were diagnosed with invasive listeriosis in Italy in 2014-2016 were studied. This in vitro and in vivo study explored the antibacterial and anti-virulence properties of a steam-distilled essential oil of Cannabis sativa L., which is being intensively investigated for its high content in powerful bioactive phytochemicals. Susceptibility experiments demonstrated a moderate bactericidal activity of the essential oil (Minimum Bactericidal Concentration > 2048 μg/mL). Assessment of the effects of sublethal concentrations of the essential oil on L. monocytogenes virulence traits demonstrated a significant action on motility. Listeriae were non-motile after exposure to the essential oil. Light and scanning electron microscopy documented aggregates of listeriae with the flagella trapped inside the cluster. Real-time RT-PCR experiments showed downregulation of flagellar motility genes and of the regulatory gene prfA. The ability to form biofilm and to invade Caco-2 cells was also significantly reduced. Galleria mellonella larvae infected with L. monocytogenes grown in presence of sublethal concentrations of the essential oil showed much higher survival rates compared with controls, suggesting that the extract inhibited tissue invasion. Food contamination with L. monocytogenes is a major concern for the food industry, particularly for plants making ready-to-eat and processed food. The present work provides a baseline in the study of the anti-virulence properties of the C. sativa essential oil against L. monocytogenes. Further studies are needed to understand if it could be used as an alternative agent for the control of L. monocytogenes in food processing plants.
Collapse
Affiliation(s)
- Emanuela Marini
- Unit of Microbiology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy
| | - Gloria Magi
- Unit of Microbiology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Angelica Giuliani
- Division of Pathology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Armanda Pugnaloni
- Division of Pathology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Maria Rita Rippo
- Division of Pathology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Bruna Facinelli
- Unit of Microbiology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy
| |
Collapse
|
44
|
Alleva R, Manzella N, Gaetani S, Bacchetti T, Bracci M, Ciarapica V, Monaco F, Borghi B, Amati M, Ferretti G, Tomasetti M. Mechanism underlying the effect of long-term exposure to low dose of pesticides on DNA integrity. Environ Toxicol 2018; 33:476-487. [PMID: 29359425 DOI: 10.1002/tox.22534] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 01/02/2018] [Accepted: 01/06/2018] [Indexed: 06/07/2023]
Abstract
Pesticides, including herbicides, insecticides and fungicides, are widely used in intensive agriculture. Recently, the long-term effects of pesticide exposure were found to be associated with many diseases. In this study, we evaluated the long-term effect of low-level exposure to a mixture of pesticides on DNA damage response (DDR) in relation to individual detoxifying variability. A residential population chronically exposed to pesticides was enrolled, biological/environmental pesticide levels; paroxonase 1 (PON-1) activity and 192 Q/R polymorphism and DDR were evaluated at three different periods of pesticide exposure. OGG1-dependent DNA repair activity was decreased in relation to pesticide exposure. The increase of DNA lesions and pesticide levels in the intensive pesticide-spraying period was independent on PON-1 activity. Next, human bronchial epithelial and neuronal cells were used as a model for in vitro evaluation of the mechanistic effect of pesticides. Pesticides induced mitochondrial dysfunction leading to ROS formation. ROS from mitochondria induced DNA damage, which in turn induced OGG1-dependent DNA repair activity through 8-oxoguanine DNA glycosylase 1 (OGG1) expression and activation. Even though OGG1 was overexpressed, an inhibition of its activity, associated with DNA lesion accumulation, was found at prolonged pesticide-exposure. A post-translational regulation of OGG1 by pesticide may be postulated. Taken together, long-term exposure to low-levels of pesticides affects DDR resulting in accumulation of DNA lesions that eventually may lead to cancer or neurological disorders.
Collapse
Affiliation(s)
- Renata Alleva
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
- International Society of Doctors for the Environment (ISDE), Arezzo, Italy
| | - Nicola Manzella
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Simona Gaetani
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Massimo Bracci
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Veronica Ciarapica
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Federica Monaco
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Battista Borghi
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Monica Amati
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- International Society of Doctors for the Environment (ISDE), Arezzo, Italy
- Department of Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Marco Tomasetti
- International Society of Doctors for the Environment (ISDE), Arezzo, Italy
- Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
| |
Collapse
|
45
|
Bacchetti T, Sartini D, Pozzi V, Cacciamani T, Ferretti G, Emanuelli M. Exploring the role of paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell cultures. Oncotarget 2018; 8:28785-28795. [PMID: 28430636 PMCID: PMC5438691 DOI: 10.18632/oncotarget.15674] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Accepted: 02/06/2017] [Indexed: 11/25/2022] Open
Abstract
The enzyme paraoxonase-2 (PON2) is ubiquitously expressed and exerts its antiapoptotic and antioxidative functions in several intracellular compartments.The aim of this study is to investigate the role of PON2 in bladder cancer (BC). The expression levels of PON2 in paired tumor and normal bladder tissue samples and in urinary exfoliated cells from patients affected with BC and healthy donors were evaluated. Moreover, the effect of PON2 overexpression on tumor cell proliferation and susceptibility to oxidative stress was investigated in human bladder cancer cell line T24.Our results showed that PON2 expression levels were significantly higher in BC compared with non-tumor tissue. In urinary exfoliated cells from BC patients, PON2 mRNA levels showed an inverse correlation with tumor stage (pT). Moreover, PON2 overexpression in T24 cells led to a significant increase in tumor cell proliferation and resistance to oxidative stress.The results obtained showed that PON2 could represent a molecular biomarker for bladder cancer and suggest a potential role of the enzyme as a prognostic factor for this neoplasm.
Collapse
Affiliation(s)
- Tiziana Bacchetti
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Davide Sartini
- Department of Clinical Sciences Polytechnic University of Marche, Ancona, Italy
| | - Valentina Pozzi
- New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, Ancona, Italy
| | - Tiziana Cacciamani
- Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy
| | - Gianna Ferretti
- Department of Clinical Sciences Polytechnic University of Marche, Ancona, Italy
| | - Monica Emanuelli
- Department of Clinical Sciences Polytechnic University of Marche, Ancona, Italy.,New York-Marche Structural Biology Center (NY-MaSBiC), Polytechnic University of Marche, Ancona, Italy
| |
Collapse
|
46
|
Affiliation(s)
- A. Taboni
- Department of Clinical and Experimental Sciences; University of Brescia; Brescia Italy
| | - N. Fagoni
- Department of Clinical and Experimental Sciences; University of Brescia; Brescia Italy
| | - G. Vinetti
- Department of Clinical and Experimental Sciences; University of Brescia; Brescia Italy
| | - G. Ferretti
- Department of Molecular and Translational Medicine; University of Brescia; Brescia Italy
- Departments APSI and NEUFO; University of Geneva; Geneva Switzerland
| |
Collapse
|
47
|
Sahebkar A, Reiner Z, Simental-Mendia LE, Ferretti G, Della Corte C, Nobili V. Impact of Statin Therapy on Plasma Vitamin D Levels: A Systematic Review and Meta-Analysis. Curr Pharm Des 2018; 23:861-869. [PMID: 27719645 DOI: 10.2174/1381612822666161006150542] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Accepted: 09/30/2016] [Indexed: 11/22/2022]
Abstract
BACKGROUND During recent years, treatment with statins has been suggested to induce several effect on bone status and vitamin D metabolism, interpreted as statins pleiotropic effects. Actually, the available data are not conclusive and the characteristics of this association remains unclear. AIM The purpose of this meta-analysis was therefore to investigate the possible effect of statins therapy on vitamin D serum levels based on the reported results from RCTs and observational studies. METHODS PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched to identify studies evaluating the impact of statins on plasma vitamin D concentrations from inception to September 16, 2015. A systematic assessment of bias in the included randomized controlled trials was performed using the Cochrane criteria. A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for the heterogeneity of studies in terms of demographic characteristics of populations being studied and also differences in study design and type of statin being studied. Sensitivity analysis was conducted using the leave-one-out method. RESULTS Following a multiple database search, 1422 published studies were identified; among these, 7 studies were found to be eligible and included in the systematic review and meta-analysis. Our meta-analysis of data from seven studies (including 5 RCTs) did not indicate any significant effect of statins treatment on plasma vitamin D levels. CONCLUSION Further well-designed trials are necessary to confirm these results and to define better a possible relationship between statins and vitamin D levels.
Collapse
Affiliation(s)
| | | | | | | | | | - Valerio Nobili
- Chief of Hepatometabolic Department Head of Liver Research Unit "Bambino Gesu" Children's Hospital Pzza S Onofrio, 4 00165, Rome, Italy
| |
Collapse
|
48
|
Fabi A, Alesini D, Valle E, Carbognin L, Arpino G, Montemurro F, Ciccarese M, Cannita K, Paris I, Cursano MC, Moscetti L, Ferretti G, De Laurentiis M, Zambelli A, La Verde N, Nisticò C, Gasparro S, Giannarelli D, Cognetti F. Abstract P1-17-02: Ado-trastuzumab emtansine (TDM-1) treatment and brain metastases in HER2 positive metastatic breast cancer patients: Final analysis of an italian multicenter study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-17-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Ado-trastuzumab emtansine (T-DM1) is a drug-antibody conjugate whose activity has been confirmed in HER2+ advanced breast cancer (BC) patients by the phase 3 EMILIA trial (Verma et al, NEJM 2012). Within the 991 patients enrolled in this trial, about 10% were affected with brain metastases (BM); in this subgroup, safety and efficacy of T-DM1 were confirmed although without any PFS improvement.
Patients and methods: In an Italian, multicenter, retrospective analysis involving 303 patients with advanced BC treated with T-DM1 (Fabi et al, Oncotarget 2017), we analyzed 87 patients with BM (BM-group). The study wanted to evaluate the efficacy of T-DM1 on BM; furthermore we compared BM-group with the remaining 216 patients without BM (nBM-group) in order to study outcome of disease. MRI was used as assessment imaging.
The number of extracranial metastatic sites in the BM-group and in the nBM-group was 1 for 10 (11.5%) and for 74 patients (34.3%), 2 for 23 (26.4%) and 93 (43%) patients, 3 for 25 (28.7% and 38 (17.6%) and 4 or more for 29 (33%) and 11 (5%), respectively.
In the BM-group, 5 patients (5.7%) had received surgery alone as local treatment for brain metastases, 13 (14.9%) surgery plus stereotactic radio-surgery (SRS), 4 (4.7%) surgery plus whole-brain radiotherapy (WBRT), 23 (26.5%) SRS alone, 40 (45.9%)WBRT alone and 2 (2.3%) WBRT followed by SRS. Twenty-eight patients (32.9%) and 89 (42.4%) in the BM-group and nBM-group, respectively, received T-DM1 as second line, 24 (28.2%) and 49 (23.3%) as third line and 33 (38.8%) and 72 (34.3%) as fourth line. Mean number of cycles was 6 in both groups.
Results:Among BM-group, 53 patients (60.9%) were evaluable for response. Two (3.8%) obtained brain complete response, 14 (26.4%) partial response and 13 (24.5%) stable disease [brain disease control rate: 54.7%); 24 (45.3%) progressed during T-DM1.
Regarding extracranial metastases, overall response rate was 35.1% in the BM-group and 38.3% in the nBM-group; 6 months-clinical benefit was 50.6% and 52.3%, respectively. Median PFS was 7 months in the BM-group and 8 months in the nBM-group; when T-DM1 was given as second line, median PFS was 5 months in the BM-group and 11 months in nBM-group (p=0.01) while as third, line in which 76% of patients received lapatinib/capacitabine before TDM1, median PFS was 12 and 13 months (p=NS), respectively.
Conclusions: T-DM1 showed a good activity on BM in BC patients. A better outcome was shown in patients previously treated with lapatinib. The identification of clinical and biological prognostic factors could be needed to better select more responder patients with BM to T-DM1.
Citation Format: Fabi A, Alesini D, Valle E, Carbognin L, Arpino G, Montemurro F, Ciccarese M, Cannita K, Paris I, Cursano MC, Moscetti L, Ferretti G, De Laurentiis M, Zambelli A, La Verde N, Nisticò C, Gasparro S, Giannarelli D, Cognetti F. Ado-trastuzumab emtansine (TDM-1) treatment and brain metastases in HER2 positive metastatic breast cancer patients: Final analysis of an italian multicenter study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-17-02.
Collapse
Affiliation(s)
- A Fabi
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - D Alesini
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - E Valle
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - L Carbognin
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - G Arpino
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - F Montemurro
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - M Ciccarese
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - K Cannita
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - I Paris
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - MC Cursano
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - L Moscetti
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - G Ferretti
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - M De Laurentiis
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - A Zambelli
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - N La Verde
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - C Nisticò
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - S Gasparro
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - D Giannarelli
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| | - F Cognetti
- Regina Elena National Cancer Institute, Roma, RM, Italy; Oncologia Medica, Ospedale Businco, Cagliari, RM, Italy; University Verona, Italy, Italy; University Federico II Napoli, Italy; Ospedale Vito Fazi, Lecce, Italy; Istituto Piemontese A Carattere Scientifico, Italy; Ospedale Civile, L'Aquila, Italy; Ospedale G. Gemelli, Roma, Italy; Università Campus Biomedico, Rome, Italy; Ospedale Modena, Modena, Italy; Regina Elena National Cancer Institute, Rome, Italy; Pascale Institute, Napoli, Italy; Ospedale Riuniti, Bergamo, Italy; Ospedale San Raffele, Milano, Italy
| |
Collapse
|
49
|
Ferretti G, Bacchetti T, Simental-Mendía LE, Reiner Ž, Banach M, Sahebkar A. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Cardiovasc Drugs Ther 2018; 31:197-208. [PMID: 28265881 DOI: 10.1007/s10557-017-6721-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND AND AIMS Lipoprotein(a) (Lp(a)) is a proatherogenic plasma lipoprotein and an independent risk factor for atherosclerotic cardiovascular disease. We investigated the effects of raloxifene, selective estrogen receptor modulator, on circulating Lp(a) levels in postmenopausal women using a systematic review and meta-analysis of randomized controlled trials (RCTs). METHODS To identify relevant studies, electronic databases (PUBMED, Scopus, Web of Science, and Google Scholar) were searched by up to May 2015 to find controlled trials exploring the effects of oral raloxifene treatment on plasma Lp(a) levels in postmenopausal women. A random-effects model and generic inverse variance method were used for quantitative data synthesis. RESULTS Overall, seven eligible RCTs with ten treatment arms were included in this meta-analysis. Meta-analysis suggested a significant reduction of Lp(a) levels after treatment with raloxifene (standardized mean difference (SMD) -0.42; 95% CI -0.65, -0.19; p < 0.001), which may be considered as a medium effect size. When the studies were categorized according to the administered dose, there was a significant effect in both subsets of studies with administered doses ≤60 mg/day (SMD -0.43; 95% CI -0.73, -0.13; p = 0.004) and >60 mg/day (SMD -0.36; 95% CI -0.68, -0.05; p = 0.025). No significant association between the changes in plasma concentrations of Lp(a) with dose and baseline Lp(a) levels was found in the random-effects meta-regression analysis. However, a significant inverse association was observed between the Lp(a)-lowering effect of raloxifene and duration of treatment (p = 0.001). CONCLUSIONS Results of the present meta-analysis showed a reduction in plasma Lp(a) concentrations of postmenopausal women with oral raloxifene treatment.
Collapse
Affiliation(s)
- Gianna Ferretti
- Dipartimento di Scienze cliniche Specialistiche ed Odontostomatologiche, Università Politecnica delle Marche, Ancona, Italy
| | - Tiziana Bacchetti
- Dipartimento di Scienze della Vita e dell'Ambiente, Università Politecnica delle Marche, Ancona, Italy
| | | | - Željko Reiner
- Department of Internal Medicine, University Hospital Center Zagreb, University of Zagreb School of Medicine, Kišpatićeva 12, Zagreb, Croatia
| | - Maciej Banach
- Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, Poland
| | - Amirhossein Sahebkar
- Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. .,Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. .,School of Medicine, University of Western Australia, Perth, Iran.
| |
Collapse
|
50
|
Pinsolle J, Duruisseaux M, Mondet J, Phillips Houlbracq M, Magnat N, Fauré J, Chatagnon A, De Fraipont F, Giaj Levra M, Toffart A, Ferretti G, Hainaut P, Brambilla E, Lantuejoul S, Moro-Sibilot D, Mcleer A. Détection des variants de fusion du gène ALK par séquençage massif parallèle ciblé à partir d’ARN et réponse au crizotinib dans les cancers pulmonaires non à petites cellules. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|